Confidential Treatment Request Filed With The Secretary Of The Securities And License Agreement - OSI PHARMACEUTICALS INC - 5-15-2000 by OSIP-Agreements

VIEWS: 14 PAGES: 51

									EXHIBIT 10.1 Portions of Exhibit 10.1 have been redacted and are the subject of a confidential treatment request filed with the Secretary of the Securities and Exchange Commission.

LICENSE AGREEMENT AGREEMENT made this 3rd day of January, 2000 (the "Effective Date") by and between OSI Pharmaceuticals, Inc. ("OSI"), a Delaware corporation with principal offices at 106 Charles Lindbergh Boulevard, Uniondale, New York 11553-3649, American Home Products Corporation ("AHPC"), a Delaware corporation with principal offices at Five Giralda Farms, Madison, New Jersey 07940, and American Cyanamid Company ("ACC"), a Maine corporation and wholly-owned subsidiary of AHPC with principal offices at One Campus Drive, Parsippany, New Jersey 07054. W I T N E S S E T H: WHEREAS, OSI is the owner of certain gene transcription patents and is willing to grant a license under such patents to AHPC and its Affiliates, including ACC; and WHEREAS, AHPC and its Affiliates, including ACC, are the owners of certain patents relating to yeast screening assays and AHPC and its Affiliates, including ACC, are willing to grant a license under such patents to OSI; and WHEREAS, OSI and AHPC desire to cross license their respective patents, according to the terms contained herein. NOW, THEREFORE, in consideration of the covenants and premises contained herein, the Parties agree as follows: 1. DEFINITIONS 1.1 "Affiliate" means any corporation, company, partnership, joint venture and/or firm which controls, is controlled by or is under common control with a Party. For purposes of this Section 1.1, "control" means (a) in the case of corporate entities, direct or indirect ownership of at least 50% of the stock or shares entitled to vote for the election of directors; and (b) in the case of non-corporate entities, direct or indirect ownership of at least 50% of the equity interest with the power to direct the management and policies of such non-corporate entities. 1.2 ** 1.3 "AHPC Licensed Compound" means any compounds or other molecules, and any compounds or other molecules derived therefrom, the identification, development, manufacture, use, importation or sale of which in a specific

** This portion has been redacted pursuant to a request for confidential treatment.

country would, in the absence of this Agreement, infringe an issued or granted claim in an AHPC Licensed Patent. 1.4 "AHPC Licensed Patents" means the U.S. patents and patent applications listed on Exhibit A hereto, any patent applications filed prior or subsequent to the Effective Date that claim the benefit of the filing date of any

LICENSE AGREEMENT AGREEMENT made this 3rd day of January, 2000 (the "Effective Date") by and between OSI Pharmaceuticals, Inc. ("OSI"), a Delaware corporation with principal offices at 106 Charles Lindbergh Boulevard, Uniondale, New York 11553-3649, American Home Products Corporation ("AHPC"), a Delaware corporation with principal offices at Five Giralda Farms, Madison, New Jersey 07940, and American Cyanamid Company ("ACC"), a Maine corporation and wholly-owned subsidiary of AHPC with principal offices at One Campus Drive, Parsippany, New Jersey 07054. W I T N E S S E T H: WHEREAS, OSI is the owner of certain gene transcription patents and is willing to grant a license under such patents to AHPC and its Affiliates, including ACC; and WHEREAS, AHPC and its Affiliates, including ACC, are the owners of certain patents relating to yeast screening assays and AHPC and its Affiliates, including ACC, are willing to grant a license under such patents to OSI; and WHEREAS, OSI and AHPC desire to cross license their respective patents, according to the terms contained herein. NOW, THEREFORE, in consideration of the covenants and premises contained herein, the Parties agree as follows: 1. DEFINITIONS 1.1 "Affiliate" means any corporation, company, partnership, joint venture and/or firm which controls, is controlled by or is under common control with a Party. For purposes of this Section 1.1, "control" means (a) in the case of corporate entities, direct or indirect ownership of at least 50% of the stock or shares entitled to vote for the election of directors; and (b) in the case of non-corporate entities, direct or indirect ownership of at least 50% of the equity interest with the power to direct the management and policies of such non-corporate entities. 1.2 ** 1.3 "AHPC Licensed Compound" means any compounds or other molecules, and any compounds or other molecules derived therefrom, the identification, development, manufacture, use, importation or sale of which in a specific

** This portion has been redacted pursuant to a request for confidential treatment.

country would, in the absence of this Agreement, infringe an issued or granted claim in an AHPC Licensed Patent. 1.4 "AHPC Licensed Patents" means the U.S. patents and patent applications listed on Exhibit A hereto, any patent applications filed prior or subsequent to the Effective Date that claim the benefit of the filing date of any patent application listed on Exhibit A and any reissues, extensions, substitutions, confirmations, re-registrations, re-examinations, continuations, divisionals or continuations-in-part of the foregoing patents and patent applications, as well as all foreign counterparts thereof. 1.5 "AHPC Licensed Product" means any product for sale by OSI or its Affiliates to a Third Party in the OSI Field of Use which contains an AHPC Licensed Compound. 1.6 "Confidential Information" means all information received by a Party from another Party pursuant to this Agreement, which is deemed confidential by the disclosing Party and is designated confidential at the time the

country would, in the absence of this Agreement, infringe an issued or granted claim in an AHPC Licensed Patent. 1.4 "AHPC Licensed Patents" means the U.S. patents and patent applications listed on Exhibit A hereto, any patent applications filed prior or subsequent to the Effective Date that claim the benefit of the filing date of any patent application listed on Exhibit A and any reissues, extensions, substitutions, confirmations, re-registrations, re-examinations, continuations, divisionals or continuations-in-part of the foregoing patents and patent applications, as well as all foreign counterparts thereof. 1.5 "AHPC Licensed Product" means any product for sale by OSI or its Affiliates to a Third Party in the OSI Field of Use which contains an AHPC Licensed Compound. 1.6 "Confidential Information" means all information received by a Party from another Party pursuant to this Agreement, which is deemed confidential by the disclosing Party and is designated confidential at the time the information is disclosed, subject to the exceptions set forth in Section 6. 1.7 "Cosmeceuticals" means compounds, or assays for discovering compounds, useful for (a) stimulation or control of hair growth, (b) prevention or reversal of wrinkling of the skin, and (c) alteration of skin or hair pigmentation. 1.8 "Licensed Patent" means an AHPC Licensed Patent or an OSI Licensed Patent. 1.9 "Licensed Product" means an AHPC Licensed Product or an OSI Licensed Product. 1.10 "OSI Field of Use" means the internal research and development by OSI and its Third Party collaborators, without the right to sublicense, of products for human therapeutic purposes. 1.11 "OSI Licensed Compound" means any compounds or other molecules, and any compounds or other molecules derived therefrom, the identification, development, manufacture, use, importation or sale of which in a specific country would, in the absence of this Agreement, infringe an issued or granted claim in an OSI Licensed Patent. 1.12 "OSI Licensed Patents" means the U.S. patents and patent applications listed on Exhibit B hereto, any patent applications filed prior or subsequent to the Effective Date that claim the benefit of the filing date of any patent application listed on Exhibit B and any reissues, extensions, substitutions, confirmations, re-registrations, re-examinations, continuations, divisionals or continuations-in-part of the foregoing patents and patent applications, as well as all foreign counterparts thereof. 2

1.13 "OSI Licensed Product" means any product for sale by AHPC or its Affiliates to a Third Party in the AHPC Field of Use which contains an OSI Licensed Compound. 1.14 "Party" means any of AHPC, ACC or OSI and "Parties" means AHPC, ACC and OSI, collectively. 1.15 "Person" means any individual, corporation, limited liability company, cooperative, partnership, trust, unincorporated association or any other entity which possesses a juridical personality, including any governmental authorities or body of competent jurisdiction; pronouns, when referring to a Person, shall have a similar extended meaning. 1.16 "Third Party" means any entity other than AHPC or its Affiliates, including ACC, or OSI or its Affiliates. 2. LICENSE GRANT 2.1 By OSI.
2.1.1 OSI hereby grants to AHPC and its Affiliates, including

1.13 "OSI Licensed Product" means any product for sale by AHPC or its Affiliates to a Third Party in the AHPC Field of Use which contains an OSI Licensed Compound. 1.14 "Party" means any of AHPC, ACC or OSI and "Parties" means AHPC, ACC and OSI, collectively. 1.15 "Person" means any individual, corporation, limited liability company, cooperative, partnership, trust, unincorporated association or any other entity which possesses a juridical personality, including any governmental authorities or body of competent jurisdiction; pronouns, when referring to a Person, shall have a similar extended meaning. 1.16 "Third Party" means any entity other than AHPC or its Affiliates, including ACC, or OSI or its Affiliates. 2. LICENSE GRANT 2.1 By OSI.
2.1.1 OSI hereby grants to AHPC and its Affiliates, including ACC, for the AHPC Field of Use, a nonexclusive, nontransferable (other than as permitted by Section 8.1), worldwide, ** license under the OSI Licensed Patents to make, have made, use, sell, offer for sale, import, export, or otherwise exploit OSI Licensed Products. OSI agrees that commencing **

2.1.2

2.2 By AHPC. Each of AHPC and ACC hereby grants to OSI and its Affiliates, for the OSI Field of Use, a nonexclusive, nontransferable, world-wide, ** license under the AHPC License Patents owned by it to make, have made, use, sell, offer for sale, import, export or otherwise exploit AHPC Licensed Products, provided that the foregoing license shall not include the right for OSI to sell any compositions or methodologies used in the discovery or development of such AHPC Licensed Products, ** , to a Third Party or otherwise provide Third Parties (other than OSI's collaborators) with access to same. 3. PATENT RIGHTS AND INFRINGEMENT 3.1 OSI shall have complete control, at its expense and within its sole discretion, over the prosecution, maintenance and enforcement of the OSI Licensed Patents.

** This portion has been redacted pursuant to a request for confidential treatment. 3

When information comes to the attention of AHPC or its Affiliates, including ACC, that an OSI Licensed Patent has been or is threatened to be infringed by a Third Party, AHPC shall promptly bring such infringement or threatened infringement to the attention of OSI. OSI shall have the right (but not the obligation), in its sole discretion, at its own risk and expense, and using counsel of its choice, to take such action as it may deem necessary to prosecute or prevent such infringement. 3.2 AHPC shall have complete control, at its expense and within its sole discretion, over the prosecution, maintenance and enforcement of the AHPC Licensed Patents. When information comes to the attention of OSI that an AHPC Licensed Patent has been or is threatened to be infringed by a Third Party, OSI shall promptly bring such infringement or threatened infringement to the attention of AHPC. AHPC shall have the right (but not the obligation), in its sole discretion, at its own risk and expense, and using counsel of its choice, to take such action as it may deem necessary to prosecute or prevent such infringement. 3.3 If AHPC or any of its customers shall be sued by a Third Party for infringement of a patent because of the

When information comes to the attention of AHPC or its Affiliates, including ACC, that an OSI Licensed Patent has been or is threatened to be infringed by a Third Party, AHPC shall promptly bring such infringement or threatened infringement to the attention of OSI. OSI shall have the right (but not the obligation), in its sole discretion, at its own risk and expense, and using counsel of its choice, to take such action as it may deem necessary to prosecute or prevent such infringement. 3.2 AHPC shall have complete control, at its expense and within its sole discretion, over the prosecution, maintenance and enforcement of the AHPC Licensed Patents. When information comes to the attention of OSI that an AHPC Licensed Patent has been or is threatened to be infringed by a Third Party, OSI shall promptly bring such infringement or threatened infringement to the attention of AHPC. AHPC shall have the right (but not the obligation), in its sole discretion, at its own risk and expense, and using counsel of its choice, to take such action as it may deem necessary to prosecute or prevent such infringement. 3.3 If AHPC or any of its customers shall be sued by a Third Party for infringement of a patent because of the research, development, manufacture, use or sale of OSI Licensed Products, AHPC shall promptly notify OSI in writing of the institution of such suit. OSI shall have all authority over such suit (including the right to exclusive control of the defense of any such suit, action, or proceeding and the exclusive right to compromise, litigate, settle, or otherwise dispose of any such suit, action, or proceeding). AHPC and its Affiliates shall provide information and assistance necessary to defend or settle any such suit, action or proceeding at OSI's expense. If OSI does not elect to manage the defense against such infringement action or fails to take appropriate and diligent action with respect to such defense, then AHPC shall have the right to assume such defense, at its own cost and expense. 3.4 If OSI or any of its customers shall be sued by a Third Party for infringement of a patent because of the research, development, manufacture, use or sale of AHPC Licensed Products, OSI shall promptly notify AHPC in writing of the institution of such suit. AHPC shall have all authority over such suit (including the right to exclusive control of the defense of any such suit, action, or proceeding and the exclusive right to compromise, litigate, settle, or otherwise dispose of any such suit, action, or proceeding). OSI shall provide information and assistance necessary to defend or settle any such suit, action or proceeding at AHPC's expense. If AHPC does not elect to manage the defense against such infringement action or fails to take appropriate and diligent action with respect to such defense, then OSI shall have the right to assume such defense, at its own cost and expense. 4

4. REPRESENTATIONS AND WARRANTIES 4.1 Representations and Warranties of AHPC, ACC and OSI. As of the Effective Date, each Party hereby represents and warrants that:
4.1.1 Corporate Power. Such Party is duly organized and validly existing and in good standing under the laws of the state of its incorporation and has all requisite corporate power and authority to enter into this Agreement and to carry out the provisions hereof. Due Authorization. Such Party is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder. Binding Agreement. This Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. Patents. Such Party acknowledges and agrees that nothing in this Agreement shall be construed as a warranty or representation that any Licensed Product is, or will be,

4.1.2

4.1.3

4.1.4

4. REPRESENTATIONS AND WARRANTIES 4.1 Representations and Warranties of AHPC, ACC and OSI. As of the Effective Date, each Party hereby represents and warrants that:
4.1.1 Corporate Power. Such Party is duly organized and validly existing and in good standing under the laws of the state of its incorporation and has all requisite corporate power and authority to enter into this Agreement and to carry out the provisions hereof. Due Authorization. Such Party is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder. Binding Agreement. This Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. Patents. Such Party acknowledges and agrees that nothing in this Agreement shall be construed as a warranty or representation that any Licensed Product is, or will be, free from infringement of patents of Third Parties. Right to License. Such Party owns all right, title and interest in and to the Licensed Patents licensed by it hereunder. Patents. There are no pending or, to its knowledge, threatened suits, claims, or proceedings including interferences or opposition proceedings relating to the Licensed Patents licensed by it hereunder, other than normal patent prosecution proceedings.

4.1.2

4.1.3

4.1.4

4.1.5

4.1.6

5. INDEMNITY 5.1 AHPC shall indemnify and hold harmless OSI, its Affiliates and all directors, officers, employees and agents of OSI and its Affiliates from and against any and all claims, demands, actions, liabilities, judgments, costs and expenses of whatever kind, whether based on contract, negligence, strict liability or statutory liability, including, without limitation, attorneys' fees and costs of defense, arising out of or related in any way to the clinical testing or use, production, sale, offer to sell, import, export or other exploitation of OSI Licensed Products by AHPC or its Affiliates under this Agreement, other than such as arise out of or are related to OSI's gross negligence or intentional misconduct. 5

5.2 OSI shall indemnify and hold harmless AHPC, its Affiliates and all directors, officers, employees and agents of AHPC and its Affiliates from and against any and all claims, demands, actions, liabilities, judgments, costs and expenses of whatever kind, whether based on contract, negligence, strict liability or statutory liability, including, without limitation, attorneys' fees and costs of defense, arising out of or related in any way to the clinical testing or use, production, sale, offer to sell, import, export or other exploitation of AHPC Licensed Products by OSI or its Affiliates under this Agreement, other than such as arise out of or are related to AHPC's gross negligence or intentional misconduct. 5.3 Each of AHPC and OSI shall indemnify and hold the other and the other's Affiliates harmless with respect to any injury, loss or cost resulting from the breach of any representation or warranty provided pursuant to Section 4 hereof.

5.2 OSI shall indemnify and hold harmless AHPC, its Affiliates and all directors, officers, employees and agents of AHPC and its Affiliates from and against any and all claims, demands, actions, liabilities, judgments, costs and expenses of whatever kind, whether based on contract, negligence, strict liability or statutory liability, including, without limitation, attorneys' fees and costs of defense, arising out of or related in any way to the clinical testing or use, production, sale, offer to sell, import, export or other exploitation of AHPC Licensed Products by OSI or its Affiliates under this Agreement, other than such as arise out of or are related to AHPC's gross negligence or intentional misconduct. 5.3 Each of AHPC and OSI shall indemnify and hold the other and the other's Affiliates harmless with respect to any injury, loss or cost resulting from the breach of any representation or warranty provided pursuant to Section 4 hereof. 6. CONFIDENTIALITY 6.1 Confidential Information. Except as expressly provided herein, the Parties agree that the receiving Party shall keep completely confidential and shall not publish or otherwise disclose to another Party and shall not use for any purpose other than to perform the purposes contemplated by this Agreement any Confidential Information furnished to it by the disclosing Party hereto pursuant to this Agreement, except to the extent that it can be established by the receiving Party by competent proof that such Confidential Information (a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure; (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; (d) was lawfully disclosed to the receiving Party by a person other than a Party hereto; or (e) was independently developed by the receiving Party. 6.2 Permitted Use and Disclosures. Each Party hereto may use or disclose Confidential Information disclosed to it by another Parry to the extent such use or disclosure is reasonably necessary in filing or prosecuting patent applications, prosecuting or defending litigation, complying with applicable law, governmental regulation or court order, submitting information to tax or other governmental authorities, or otherwise exercising its rights hereunder, provided that if a Party is required to make any such disclosure of another Party's Confidential Information, it will give reasonable advance notice to the latter Party of such disclosure and, save to the extent inappropriate in the case of patent applications, will use reasonable efforts to secure confidential treatment of such information prior to its disclosure (whether through protective orders or otherwise). 6

6.3 Confidential Terms. Except as expressly provided herein, each Party agrees not to disclose any terms of this Agreement to a Third Party without the consent of the other Parties; provided, however, that each Party reserves the right to make reasonable disclosures as required by securities or other applicable laws, or to actual or prospective investors or corporate partners, or to accountants, attorneys and other professional advisors on a need-to-know basis under circumstances that reasonably ensure the confidentiality thereof, or to the extent required by law. If such Confidential Information is to become public information by such disclosure the disclosing Party must obtain the written consent of the non-disclosing Parties in order to obtain protection of the Confidential Information if necessary. 6.4 Press Release. Notwithstanding the foregoing, the Parties shall agree upon a press release to announce the execution of this Agreement. Thereafter, OSI, AHPC and ACC may each disclose to Third Parties the information contained in such press release without the need for further approval by the other. 7. TERM AND TERMINATION 7.1 This Agreement is effective as of the Effective Date and shall continue in full force and effect, with respect to a Party, on a country by country basis until the last expiration date of all patents encompassed within the Licensed Patents licensed to such Party hereunder. 7.2 If a Party shall fail in any material respect to perform or observe any term, covenant or understanding

6.3 Confidential Terms. Except as expressly provided herein, each Party agrees not to disclose any terms of this Agreement to a Third Party without the consent of the other Parties; provided, however, that each Party reserves the right to make reasonable disclosures as required by securities or other applicable laws, or to actual or prospective investors or corporate partners, or to accountants, attorneys and other professional advisors on a need-to-know basis under circumstances that reasonably ensure the confidentiality thereof, or to the extent required by law. If such Confidential Information is to become public information by such disclosure the disclosing Party must obtain the written consent of the non-disclosing Parties in order to obtain protection of the Confidential Information if necessary. 6.4 Press Release. Notwithstanding the foregoing, the Parties shall agree upon a press release to announce the execution of this Agreement. Thereafter, OSI, AHPC and ACC may each disclose to Third Parties the information contained in such press release without the need for further approval by the other. 7. TERM AND TERMINATION 7.1 This Agreement is effective as of the Effective Date and shall continue in full force and effect, with respect to a Party, on a country by country basis until the last expiration date of all patents encompassed within the Licensed Patents licensed to such Party hereunder. 7.2 If a Party shall fail in any material respect to perform or observe any term, covenant or understanding contained in this Agreement or in any of the other documents or instruments delivered pursuant to, or concurrently with, this Agreement, and any such failure shall remain unremedied for ** days after written notice to the defaulting Party, the Party not responsible may, by notice to the defaulting Party, terminate the license granted by such Party to the defaulting Party. 7.3 OSI shall have the right to terminate the Agreement if either AHPC or ACC makes an assignment for the benefit of its creditors, becomes insolvent, files a petition in bankruptcy, petitions or applies to any tribunal for the appointment of a custodian, receiver or any trustee for it or a substantial part of its assets, or commences any proceeding under any bankruptcy, reorganization, arrangement, readjustment of debt, dissolution or liquidation law or statute of any jurisdiction, whether now or hereafter in effect; or if there has been filed any such petition or application against either AHPC or ACC, or any such proceeding has been commenced against it, in which an order for relief is entered or which remains

** This portion has been redacted pursuant to a request for confidential treatment. 7

undismissed for a period of 60 days or more; or if either AHPC or ACC, by any act or omission, indicates its consent to, approval of or acquiescence in, any such petition, application or proceeding or order for relief or the appointment of a custodian, receiver or any trustee for it or any substantial part of any of its properties, or is the subject of any such custodianship, receivership or trusteeship that continues undischarged for a period of 60 days or more. 7.4 AHPC and ACC shall have the right to terminate the Agreement if OSI makes an assignment for the benefit of its creditors, becomes insolvent, files a petition in bankruptcy, petitions or applies to any tribunal for the appointment of a custodian, receiver or any trustee for it or a substantial part of its assets, or commences any proceeding under any bankruptcy, reorganization, arrangement, readjustment of debt, dissolution or liquidation law or statute of any jurisdiction, whether now or hereafter in effect; or if there has been filed any such petition or application against OSI, or any such proceeding has been commenced against it, in which an order for relief is entered or which remains undismissed for a period of 60 days or more; or if OSI, by any act or omission, indicates its consent to, approval of or acquiescence in, any such petition, application or proceeding or order for relief or the appointment of a custodian, receiver or any trustee for it or any substantial part of any of its properties, or is the subject of any such custodianship, receivership or trusteeship that continues undischarged for a period of 60 days or more.

undismissed for a period of 60 days or more; or if either AHPC or ACC, by any act or omission, indicates its consent to, approval of or acquiescence in, any such petition, application or proceeding or order for relief or the appointment of a custodian, receiver or any trustee for it or any substantial part of any of its properties, or is the subject of any such custodianship, receivership or trusteeship that continues undischarged for a period of 60 days or more. 7.4 AHPC and ACC shall have the right to terminate the Agreement if OSI makes an assignment for the benefit of its creditors, becomes insolvent, files a petition in bankruptcy, petitions or applies to any tribunal for the appointment of a custodian, receiver or any trustee for it or a substantial part of its assets, or commences any proceeding under any bankruptcy, reorganization, arrangement, readjustment of debt, dissolution or liquidation law or statute of any jurisdiction, whether now or hereafter in effect; or if there has been filed any such petition or application against OSI, or any such proceeding has been commenced against it, in which an order for relief is entered or which remains undismissed for a period of 60 days or more; or if OSI, by any act or omission, indicates its consent to, approval of or acquiescence in, any such petition, application or proceeding or order for relief or the appointment of a custodian, receiver or any trustee for it or any substantial part of any of its properties, or is the subject of any such custodianship, receivership or trusteeship that continues undischarged for a period of 60 days or more. 8. MISCELLANEOUS 8.1 Binding Effect; Assignment. This Agreement shall be binding upon the Parties' respective successors and permitted assigns. Neither Party may assign this Agreement or any of its rights or obligations hereunder without the prior written consent of the other Party (not to be unreasonably withheld) except that either Party may assign this Agreement as part of a merger or consolidation in which the surviving entity assumes all of the Party's rights and obligations hereunder or a sale of substantially all of the assets of such Party to which this Agreement relates. In addition, if AHPC sells to a Third Party all of the stock of ACC or if ACC sells all or substantially all of its assets to a Third Party, AHPC or ACC, as the case may be, may assign the license granted by OSI in Section 2.1 to such Third Party purchaser, without the consent of OSI, only to the extent that such license is for the ** (i.e., subsection (b) of Section 1.1), provided that such Third Party purchaser assumes the obligations of AHPC or ACC, as the case

** This portion has been redacted pursuant to a request for confidential treatment. 8

may be, to grant the license set forth in Section 2.2. In the event of such a sale, the license granted in Section 2.1 to AHPC shall remain in effect as to AHPC and its Affiliates only with respect to the research and development of ** (i.e., subsection (a) of Section 1.1). 8.2 Effect of Waiver. No waiver of any default, condition, provisions or breach of this Agreement shall be deemed to imply or constitute a waiver of any other default, condition, provision or breach of this Agreement. 8.3 Force Majeure. No Party shall lose any rights hereunder or be liable to the other Parties for damages or losses (except for payment obligations) on account of failure of performance by the defaulting Party if the failure is occasioned by war, strike, fire, acts of God, earthquake, flood, lockout, embargo, governmental acts or orders or restrictions, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence or intentional conduct or misconduct of the nonperforming Party, and such Party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a Party be required to settle any labor dispute or disturbance. 8.4 Amendment. No modification, supplement to or waiver of this Agreement or any of the provisions hereof or any Exhibit hereto shall be binding upon a Party hereto unless made in writing and duly signed by an authorized representative of OSI, AHPC or ACC. 8.5 Entire Agreement. This Agreement, including the Exhibits attached hereto, sets forth the entire understanding

may be, to grant the license set forth in Section 2.2. In the event of such a sale, the license granted in Section 2.1 to AHPC shall remain in effect as to AHPC and its Affiliates only with respect to the research and development of ** (i.e., subsection (a) of Section 1.1). 8.2 Effect of Waiver. No waiver of any default, condition, provisions or breach of this Agreement shall be deemed to imply or constitute a waiver of any other default, condition, provision or breach of this Agreement. 8.3 Force Majeure. No Party shall lose any rights hereunder or be liable to the other Parties for damages or losses (except for payment obligations) on account of failure of performance by the defaulting Party if the failure is occasioned by war, strike, fire, acts of God, earthquake, flood, lockout, embargo, governmental acts or orders or restrictions, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence or intentional conduct or misconduct of the nonperforming Party, and such Party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a Party be required to settle any labor dispute or disturbance. 8.4 Amendment. No modification, supplement to or waiver of this Agreement or any of the provisions hereof or any Exhibit hereto shall be binding upon a Party hereto unless made in writing and duly signed by an authorized representative of OSI, AHPC or ACC. 8.5 Entire Agreement. This Agreement, including the Exhibits attached hereto, sets forth the entire understanding and agreement of the Parties as to the subject matter hereof, and there are no other understandings, representations or promises, written or verbal, not set forth herein on which a Party has relied. 8.6 Notices. All notices under this Agreement shall be given in writing and shall be addressed to the Parties at the following addresses:
For OSI: OSI Pharmaceuticals, Inc. 106 Charles Lindbergh Blvd. Uniondale, NY 11553 Attn: Chief Executive Officer

---------------------

** This portion has been redacted pursuant to a request for confidential treatment. 9
For AHPC: American Home Products c/o Wyeth-Ayerst Research 87 Cambridge Park Drive Cambridge, MA 02140 Attn: Vice President, Law American Cyanamid Corporation One Campus Drive Parsippany, NJ 07054 Attn: Director, Technology Assessment and Acquisition

For ACC:

Notices shall be in writing and shall be deemed delivered when received, if delivered by hand, courier or overnight delivery service, or on the second business day following mailing, if sent by first-class certified or registered mail, postage prepaid, and return receipt requested. 8.7 Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, applicable to agreements made in New York except that the federal laws of the United States shall apply to questions regarding the validity or infringement or enforceability of United States federal patents. The parties hereto agree that the state and federal courts sitting in the state and city of New York shall be the proper forums for any legal controversy arising in connection with this Agreement and the parties irrevocably and unconditionally consent to the non-exclusive jurisdiction of such courts for such purposes.

For AHPC:

American Home Products c/o Wyeth-Ayerst Research 87 Cambridge Park Drive Cambridge, MA 02140 Attn: Vice President, Law American Cyanamid Corporation One Campus Drive Parsippany, NJ 07054 Attn: Director, Technology Assessment and Acquisition

For ACC:

Notices shall be in writing and shall be deemed delivered when received, if delivered by hand, courier or overnight delivery service, or on the second business day following mailing, if sent by first-class certified or registered mail, postage prepaid, and return receipt requested. 8.7 Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, applicable to agreements made in New York except that the federal laws of the United States shall apply to questions regarding the validity or infringement or enforceability of United States federal patents. The parties hereto agree that the state and federal courts sitting in the state and city of New York shall be the proper forums for any legal controversy arising in connection with this Agreement and the parties irrevocably and unconditionally consent to the non-exclusive jurisdiction of such courts for such purposes. 8.8 Severability. This Agreement is intended to be severable. If any provision of this Agreement is or becomes invalid, is ruled illegal by a court of competent jurisdiction or is deemed unenforceable under the current applicable law from time to time in effect during the term hereof, it is the intention of the Parties that the remainder of this Agreement shall not be affected thereby and shall continue to be construed to the maximum extent permitted by law at such time. It is further the intention of the Parties that in lieu of each such provision which is invalid, illegal, or unenforceable, there shall be substituted or added as part of this Agreement by such court of competent jurisdiction a provision which shall be as similar as possible in terms of the economic and business objectives intended by the Parties, to such invalid, illegal or unenforceable provision, but shall be valid, legal and enforceable. 8.9 Independent Contractors. The Parties hereto are acting as independent contractors and shall not be considered partners, joint venturers or agents of the other. Except as expressly provided herein, no Party shall have the right to act on behalf of, or to bind, the other. 10

8.10 Headings; Counterparts. Captions and paragraph headings are for convenience only and shall not form an interpretative part of this Agreement. This Agreement may be executed in two or more counterparts, each of which will be deemed an original. 11

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written. OSI PHARMACEUTICALS, INC.
By: /s/ Colin Goddard ------------------------------------------Name: Colin Goddard, Ph.D. Title: President and Chief Executive Officer

AMERICAN HOME PRODUCTS CORPORATION

8.10 Headings; Counterparts. Captions and paragraph headings are for convenience only and shall not form an interpretative part of this Agreement. This Agreement may be executed in two or more counterparts, each of which will be deemed an original. 11

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written. OSI PHARMACEUTICALS, INC.
By: /s/ Colin Goddard ------------------------------------------Name: Colin Goddard, Ph.D. Title: President and Chief Executive Officer

AMERICAN HOME PRODUCTS CORPORATION
By: /s/ Gerald A. Jibilian ------------------------------------------Name: Gerald A. Jibilian Title: Vice President and Associate General Counsel

AMERICAN CYANAMID COMPANY
By: /s/ Gerald A. Jibilian ------------------------------------------Name: Gerald A. Jibilian Title: Vice President and Associate General Counsel

12

EXHIBIT A **

** This portion has been redacted pursuant to a request for confidential treatment.

EXHIBIT B **

** This portion has been redacted pursuant to a request for confidential treatment.

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written. OSI PHARMACEUTICALS, INC.
By: /s/ Colin Goddard ------------------------------------------Name: Colin Goddard, Ph.D. Title: President and Chief Executive Officer

AMERICAN HOME PRODUCTS CORPORATION
By: /s/ Gerald A. Jibilian ------------------------------------------Name: Gerald A. Jibilian Title: Vice President and Associate General Counsel

AMERICAN CYANAMID COMPANY
By: /s/ Gerald A. Jibilian ------------------------------------------Name: Gerald A. Jibilian Title: Vice President and Associate General Counsel

12

EXHIBIT A **

** This portion has been redacted pursuant to a request for confidential treatment.

EXHIBIT B **

** This portion has been redacted pursuant to a request for confidential treatment.

EXHIBIT 10.2 YEAST TECHNOLOGY LICENSE AGREEMENT YEAST TECHNOLOGY LICENSE AGREEMENT (the "Agreement"), dated as of February 15, 2000, by and between Cadus Pharmaceutical Corporation, a Delaware corporation with offices at 767 Fifth Avenue, New York, New York 10153 ("CADUS") and OSI Pharmaceuticals, Inc., a Delaware corporation with offices at

EXHIBIT A **

** This portion has been redacted pursuant to a request for confidential treatment.

EXHIBIT B **

** This portion has been redacted pursuant to a request for confidential treatment.

EXHIBIT 10.2 YEAST TECHNOLOGY LICENSE AGREEMENT YEAST TECHNOLOGY LICENSE AGREEMENT (the "Agreement"), dated as of February 15, 2000, by and between Cadus Pharmaceutical Corporation, a Delaware corporation with offices at 767 Fifth Avenue, New York, New York 10153 ("CADUS") and OSI Pharmaceuticals, Inc., a Delaware corporation with offices at 106 Charles Lindbergh Boulevard, Uniondale, New York 11533 ("OSI"). WITNESSETH: WHEREAS, CADUS is the owner of, or has acquired the rights to, CADUS Technology; and WHEREAS, OSI desires to obtain a non-exclusive license for the use and practice of CADUS Technology, and CADUS is willing to grant such non-exclusive license, upon the terms and conditions hereinafter set forth; NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants and agreements of the Parties contained in this Agreement, the Parties agree as follows: 1. DEFINITIONS For the purposes of this Agreement, the following terms shall have the meanings set forth in this Section 1: "CADUS Patents" shall mean all patents and patent applications to the extent they claim CADUS Technology, which are or become owned by CADUS or to which CADUS otherwise has, now or in the future, the right to grant licenses. Included within the definition of CADUS Patents are all continuations, continuations-in-part, divisions, patents of addition, reissues, renewals, extensions, registrations, confirmations, re-examinations thereof and any provisional applications. "CADUS Technology" shall mean all proprietary inventions, improvements, discoveries, claims, formulae, processes, trade secrets and technologies owned by CADUS or to which CADUS has the right to grant licenses or sublicenses as of the Effective Date, relating to technology involving the transfection, expression and functional coupling of Targets into yeast cells and mammalian cell lines and the development of such yeast cells and mammalian cell lines as screening assays for the discovery of human diagnostics and therapeutics. "CADUS Technology" shall include, without limitation, the bioinformatics databases owned by CADUS required to fully utilize and develop the CADUS Technology.

EXHIBIT B **

** This portion has been redacted pursuant to a request for confidential treatment.

EXHIBIT 10.2 YEAST TECHNOLOGY LICENSE AGREEMENT YEAST TECHNOLOGY LICENSE AGREEMENT (the "Agreement"), dated as of February 15, 2000, by and between Cadus Pharmaceutical Corporation, a Delaware corporation with offices at 767 Fifth Avenue, New York, New York 10153 ("CADUS") and OSI Pharmaceuticals, Inc., a Delaware corporation with offices at 106 Charles Lindbergh Boulevard, Uniondale, New York 11533 ("OSI"). WITNESSETH: WHEREAS, CADUS is the owner of, or has acquired the rights to, CADUS Technology; and WHEREAS, OSI desires to obtain a non-exclusive license for the use and practice of CADUS Technology, and CADUS is willing to grant such non-exclusive license, upon the terms and conditions hereinafter set forth; NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants and agreements of the Parties contained in this Agreement, the Parties agree as follows: 1. DEFINITIONS For the purposes of this Agreement, the following terms shall have the meanings set forth in this Section 1: "CADUS Patents" shall mean all patents and patent applications to the extent they claim CADUS Technology, which are or become owned by CADUS or to which CADUS otherwise has, now or in the future, the right to grant licenses. Included within the definition of CADUS Patents are all continuations, continuations-in-part, divisions, patents of addition, reissues, renewals, extensions, registrations, confirmations, re-examinations thereof and any provisional applications. "CADUS Technology" shall mean all proprietary inventions, improvements, discoveries, claims, formulae, processes, trade secrets and technologies owned by CADUS or to which CADUS has the right to grant licenses or sublicenses as of the Effective Date, relating to technology involving the transfection, expression and functional coupling of Targets into yeast cells and mammalian cell lines and the development of such yeast cells and mammalian cell lines as screening assays for the discovery of human diagnostics and therapeutics. "CADUS Technology" shall include, without limitation, the bioinformatics databases owned by CADUS required to fully utilize and develop the CADUS Technology.

"Covered Material" means a Hybrid Yeast Cell, a Plasmid, a Mammalian Cell Line or any material that is a Derivative of it. "Covered Material" includes a Derivative of a Derivative of a Hybrid Yeast Cell, a Plasmid or a Mammalian Cell Line. "Derivative" shall mean any of the following: (1) any substance derived from or expressed or modified by a Hybrid Yeast Cell, a Plasmid or a Mammalian Cell Line; (ii) any substance that contains or incorporates a Hybrid Yeast Cell, a Plasmid or a Mammalian Cell Line; or (iii) any fragment of any of the foregoing. "Effective Date" shall mean the date of this Agreement as set forth at the beginning of this Agreement.

EXHIBIT 10.2 YEAST TECHNOLOGY LICENSE AGREEMENT YEAST TECHNOLOGY LICENSE AGREEMENT (the "Agreement"), dated as of February 15, 2000, by and between Cadus Pharmaceutical Corporation, a Delaware corporation with offices at 767 Fifth Avenue, New York, New York 10153 ("CADUS") and OSI Pharmaceuticals, Inc., a Delaware corporation with offices at 106 Charles Lindbergh Boulevard, Uniondale, New York 11533 ("OSI"). WITNESSETH: WHEREAS, CADUS is the owner of, or has acquired the rights to, CADUS Technology; and WHEREAS, OSI desires to obtain a non-exclusive license for the use and practice of CADUS Technology, and CADUS is willing to grant such non-exclusive license, upon the terms and conditions hereinafter set forth; NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants and agreements of the Parties contained in this Agreement, the Parties agree as follows: 1. DEFINITIONS For the purposes of this Agreement, the following terms shall have the meanings set forth in this Section 1: "CADUS Patents" shall mean all patents and patent applications to the extent they claim CADUS Technology, which are or become owned by CADUS or to which CADUS otherwise has, now or in the future, the right to grant licenses. Included within the definition of CADUS Patents are all continuations, continuations-in-part, divisions, patents of addition, reissues, renewals, extensions, registrations, confirmations, re-examinations thereof and any provisional applications. "CADUS Technology" shall mean all proprietary inventions, improvements, discoveries, claims, formulae, processes, trade secrets and technologies owned by CADUS or to which CADUS has the right to grant licenses or sublicenses as of the Effective Date, relating to technology involving the transfection, expression and functional coupling of Targets into yeast cells and mammalian cell lines and the development of such yeast cells and mammalian cell lines as screening assays for the discovery of human diagnostics and therapeutics. "CADUS Technology" shall include, without limitation, the bioinformatics databases owned by CADUS required to fully utilize and develop the CADUS Technology.

"Covered Material" means a Hybrid Yeast Cell, a Plasmid, a Mammalian Cell Line or any material that is a Derivative of it. "Covered Material" includes a Derivative of a Derivative of a Hybrid Yeast Cell, a Plasmid or a Mammalian Cell Line. "Derivative" shall mean any of the following: (1) any substance derived from or expressed or modified by a Hybrid Yeast Cell, a Plasmid or a Mammalian Cell Line; (ii) any substance that contains or incorporates a Hybrid Yeast Cell, a Plasmid or a Mammalian Cell Line; or (iii) any fragment of any of the foregoing. "Effective Date" shall mean the date of this Agreement as set forth at the beginning of this Agreement. "Hybrid Yeast Cells" shall mean genetically modified yeast cells, which are owned by CADUS. "Injunction" shall mean the injunction, dated February 23, 1999, issued by the United States District Court for the Southern District of California in the SIBIA Litigation. "Mammalian Cell Lines" shall mean mammalian cell lines which are owned by CADUS. "Party" shall mean CADUS or OSI and, when used in the plural, shall mean

"Covered Material" means a Hybrid Yeast Cell, a Plasmid, a Mammalian Cell Line or any material that is a Derivative of it. "Covered Material" includes a Derivative of a Derivative of a Hybrid Yeast Cell, a Plasmid or a Mammalian Cell Line. "Derivative" shall mean any of the following: (1) any substance derived from or expressed or modified by a Hybrid Yeast Cell, a Plasmid or a Mammalian Cell Line; (ii) any substance that contains or incorporates a Hybrid Yeast Cell, a Plasmid or a Mammalian Cell Line; or (iii) any fragment of any of the foregoing. "Effective Date" shall mean the date of this Agreement as set forth at the beginning of this Agreement. "Hybrid Yeast Cells" shall mean genetically modified yeast cells, which are owned by CADUS. "Injunction" shall mean the injunction, dated February 23, 1999, issued by the United States District Court for the Southern District of California in the SIBIA Litigation. "Mammalian Cell Lines" shall mean mammalian cell lines which are owned by CADUS. "Party" shall mean CADUS or OSI and, when used in the plural, shall mean CADUS and OSI. "Person" shall mean any natural person, corporation, firm, business trust, joint venture, association, university, organization, company, partnership or other business entity, or any government or any agency or political subdivision thereof. "Plasmid" shall mean plasmids which are owned by CADUS. "Product" shall mean any compound, formulation or composition whose utility is identified using CADUS Technology. "Proprietary" shall mean, with respect to intellectual property, intellectual property that is (in whole or in part) not in the public domain at the time of transfer to the other party. "SIBIA Litigation" shall mean SIBIA Neurosciences, Inc. v. Cadus Pharmaceutical Corporation, Civil Action Number 961231 lEG POR. "Target" shall mean any biological molecular entity that provides a specific interaction with compounds, extracts, broths or other screening samples. "Third Party" shall mean any Person who or which is neither a Party nor an affiliate of a Party. 2

2. REPRESENTATIONS AND WARRANTIES 2.1 Representations and Warranties of Both Parties. Each Party represents and warrants to the other Party that: (i) it is free to enter into this Agreement; (ii) in so doing, it will not violate any other agreement to which it is a party; (iii) it has taken all corporate action necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement; and (iv) this Agreement constitutes a valid and binding obligation of such Party and is enforceable against it in accordance with its terms. 2.2 Representations and Warranties of CADUS. CADUS hereby represents and warrants to OSI that: (a) It is the owner, or a licensee, of the CADUS Technology and CADUS Patents and has the right to grant licenses therefor; and (b) During the term of this Agreement, it shall maintain its licenses to Cadus Technology licensed to it.

2. REPRESENTATIONS AND WARRANTIES 2.1 Representations and Warranties of Both Parties. Each Party represents and warrants to the other Party that: (i) it is free to enter into this Agreement; (ii) in so doing, it will not violate any other agreement to which it is a party; (iii) it has taken all corporate action necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement; and (iv) this Agreement constitutes a valid and binding obligation of such Party and is enforceable against it in accordance with its terms. 2.2 Representations and Warranties of CADUS. CADUS hereby represents and warrants to OSI that: (a) It is the owner, or a licensee, of the CADUS Technology and CADUS Patents and has the right to grant licenses therefor; and (b) During the term of this Agreement, it shall maintain its licenses to Cadus Technology licensed to it. 3. GRANT OF LICENSE 3.1 License Grant. Subject to the terms and conditions of this Agreement, CADUS hereby grants to OSI, a nonexclusive, royalty-free, worldwide right and license to use and practice the CADUS Technology and CADUS Patents other than to identify and select compounds in a method that infringes any of the claims of United States Patent No. 5,401,629 so long as any such claim remains outstanding and in effect. 3.2 No Violation of Injunction. OSI acknowledges that it has reviewed the Injunction and covenants that, in practicing the CADUS Technology and CADUS Patents, OSI 3

will not violate the terms of the Injunction or cause CADUS to be in violation of the terms of the Injunction so long as the Injunction remains outstanding and in effect. 3.3 No Right to Sublicense. OSI shall not have the right to sublicense its rights hereunder. During the term of this Agreement, OSI may practice the CADUS Technology and CADUS Patents in connection with assay development and screening for Third Parties pursuant to collaborative research programs with such Third Parties ("Third Party Collaborators"), provided that such assay development and screening takes place at OSI's facilities and is conducted by OSI personnel. In addition, a Third Party Collaborator may utilize assays developed by OSI using CADUS Technology to test compounds solely during the term and in furtherance of its collaboration with OSI. 3.4 Reservation of Rights. CADUS is retaining all rights to the CADUS Technology and CADUS Patents that are not specifically being licensed to OSI pursuant to Section 3.1 hereof. 3.5 Ownership of CADUS Technology. The Parties acknowledge and agree that all CADUS Technology is now and shall be solely owned or licensed by CADUS and that OSI shall have no right, title or interest therein except as explicitly set forth in this Agreement. 3.6 Provision of Access to CADUS Technology. Subject to the confidentiality provisions of Section 10.1, CADUS shall provide to OSI: (i) an electronic copy of its database of Covered Material, (ii) an electronic copy of its database of G protein-coupled receptors that are not proprietary to any Third Party and (iii) an electronic copy of the bioinformatics databases owned by CADUS required to fully utilize and develop the CADUS Technology. 4

4. ACCESS TO COVERED MATERIAL. 4.1 Access to Covered Material. On or prior to the date hereof, CADUS has delivered to OSI an aliquot of

will not violate the terms of the Injunction or cause CADUS to be in violation of the terms of the Injunction so long as the Injunction remains outstanding and in effect. 3.3 No Right to Sublicense. OSI shall not have the right to sublicense its rights hereunder. During the term of this Agreement, OSI may practice the CADUS Technology and CADUS Patents in connection with assay development and screening for Third Parties pursuant to collaborative research programs with such Third Parties ("Third Party Collaborators"), provided that such assay development and screening takes place at OSI's facilities and is conducted by OSI personnel. In addition, a Third Party Collaborator may utilize assays developed by OSI using CADUS Technology to test compounds solely during the term and in furtherance of its collaboration with OSI. 3.4 Reservation of Rights. CADUS is retaining all rights to the CADUS Technology and CADUS Patents that are not specifically being licensed to OSI pursuant to Section 3.1 hereof. 3.5 Ownership of CADUS Technology. The Parties acknowledge and agree that all CADUS Technology is now and shall be solely owned or licensed by CADUS and that OSI shall have no right, title or interest therein except as explicitly set forth in this Agreement. 3.6 Provision of Access to CADUS Technology. Subject to the confidentiality provisions of Section 10.1, CADUS shall provide to OSI: (i) an electronic copy of its database of Covered Material, (ii) an electronic copy of its database of G protein-coupled receptors that are not proprietary to any Third Party and (iii) an electronic copy of the bioinformatics databases owned by CADUS required to fully utilize and develop the CADUS Technology. 4

4. ACCESS TO COVERED MATERIAL. 4.1 Access to Covered Material. On or prior to the date hereof, CADUS has delivered to OSI an aliquot of each Covered Material listed on Exhibit A annexed hereto. During the term of this Agreement, CADUS shall provide to OSI an aliquot of each Covered Material not listed on Exhibit A annexed hereto that is requested by OSI in accordance with the procedure set forth below. OSI may request a Covered Material by sending to Dr. James Broach at Department of Molecular Biology, Lewis Thomas Laboratory, Princeton University, Washington Road, Princeton, New Jersey 08544 (or to such other person at such other place as CADUS may hereafter designate) a written request for such Covered Material. OSI shall pay to Dr. James Broach or such other person the incremental cost of retrieval and shipment of such Covered Material promptly after the receipt of an invoice therefor. CADUS shall ship such Covered Material to OSI within 15 days of its receipt of such written request. OSI shall have the right to use Covered Material only during the term of this Agreement. 4.2 No Transfer of Covered Material. OSI shall not provide any Covered Material to any Third Party other than a contract research organization or Third Party Collaborator that has executed a confidentiality agreement with respect to the Covered Material containing provisions similar to Section 10 hereof. OSI shall promptly destroy all Covered Material in its possession upon the termination of this Agreement. OSI will not take or send Covered Material to any location other than the facilities of OSI or a contract research organization or Third Party Collaborator that has executed a confidentiality agreement with respect to the Covered Material containing provisions similar to Section 10 hereof without CADUS's prior written consent. 5

4.3 No Warranties As To Covered Material. Any Covered Material delivered pursuant to this Agreement is understood to be experimental in nature and may have hazardous properties. It is supplied AS IS. CADUS MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE COVERED MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR

4. ACCESS TO COVERED MATERIAL. 4.1 Access to Covered Material. On or prior to the date hereof, CADUS has delivered to OSI an aliquot of each Covered Material listed on Exhibit A annexed hereto. During the term of this Agreement, CADUS shall provide to OSI an aliquot of each Covered Material not listed on Exhibit A annexed hereto that is requested by OSI in accordance with the procedure set forth below. OSI may request a Covered Material by sending to Dr. James Broach at Department of Molecular Biology, Lewis Thomas Laboratory, Princeton University, Washington Road, Princeton, New Jersey 08544 (or to such other person at such other place as CADUS may hereafter designate) a written request for such Covered Material. OSI shall pay to Dr. James Broach or such other person the incremental cost of retrieval and shipment of such Covered Material promptly after the receipt of an invoice therefor. CADUS shall ship such Covered Material to OSI within 15 days of its receipt of such written request. OSI shall have the right to use Covered Material only during the term of this Agreement. 4.2 No Transfer of Covered Material. OSI shall not provide any Covered Material to any Third Party other than a contract research organization or Third Party Collaborator that has executed a confidentiality agreement with respect to the Covered Material containing provisions similar to Section 10 hereof. OSI shall promptly destroy all Covered Material in its possession upon the termination of this Agreement. OSI will not take or send Covered Material to any location other than the facilities of OSI or a contract research organization or Third Party Collaborator that has executed a confidentiality agreement with respect to the Covered Material containing provisions similar to Section 10 hereof without CADUS's prior written consent. 5

4.3 No Warranties As To Covered Material. Any Covered Material delivered pursuant to this Agreement is understood to be experimental in nature and may have hazardous properties. It is supplied AS IS. CADUS MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE COVERED MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. 4.4 Compliance with Laws. OSI agrees to use the Covered Material in compliance with all applicable statutes and regulations including, for example, those relating to research involving the use of animals or recombinant DNA. 5. LICENSE AND MAINTENANCE FEES 5.1 License and Access Fees. In consideration of the license granted to OSI by CADUS pursuant to Section 3.1 hereof, OSI shall pay to CADUS a license fee of $100,000 payable on the Effective Date. In consideration of the access to CADUS Technology (Section 3.6) and to Covered Material (Section 4.1), OSI shall pay to CADUS an access fee of $600,000 payable on the Effective Date. 5.2 Maintenance Fee. OSI shall also pay to CADUS an annual maintenance fee of $100,000 payable on each of the first ten anniversaries of the Effective Date during the term of this Agreement. 5.3 Special Fee. If the Injunction is lifted or dissolved, OSI shall pay to CADUS a supplemental license fee of $250,000 within ten (10) days after the receipt of notice of the lifting or dissolution of the Injunction. 6

5.4 No Refunds. None of the fees paid by OSI to CADUS pursuant to Section 5 shall be refundable for any reason whatsoever. 6. PATENTS

4.3 No Warranties As To Covered Material. Any Covered Material delivered pursuant to this Agreement is understood to be experimental in nature and may have hazardous properties. It is supplied AS IS. CADUS MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE COVERED MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. 4.4 Compliance with Laws. OSI agrees to use the Covered Material in compliance with all applicable statutes and regulations including, for example, those relating to research involving the use of animals or recombinant DNA. 5. LICENSE AND MAINTENANCE FEES 5.1 License and Access Fees. In consideration of the license granted to OSI by CADUS pursuant to Section 3.1 hereof, OSI shall pay to CADUS a license fee of $100,000 payable on the Effective Date. In consideration of the access to CADUS Technology (Section 3.6) and to Covered Material (Section 4.1), OSI shall pay to CADUS an access fee of $600,000 payable on the Effective Date. 5.2 Maintenance Fee. OSI shall also pay to CADUS an annual maintenance fee of $100,000 payable on each of the first ten anniversaries of the Effective Date during the term of this Agreement. 5.3 Special Fee. If the Injunction is lifted or dissolved, OSI shall pay to CADUS a supplemental license fee of $250,000 within ten (10) days after the receipt of notice of the lifting or dissolution of the Injunction. 6

5.4 No Refunds. None of the fees paid by OSI to CADUS pursuant to Section 5 shall be refundable for any reason whatsoever. 6. PATENTS 6.1 No Obligation to Prosecute or Maintain Patents. CADUS shall not have any obligation to prosecute or maintain CADUS Patents. Notwithstanding the foregoing, CADUS shall not abandon any of the United States patent applications constituting CADUS Patents set forth on Exhibit B until such time as (i) the corresponding foreign patent application has been published or (ii) CADUS has taken the appropriate steps with the United States Patent and Trademark Office to dedicate such patent application to the public. 6.2 Infringement. OSI shall give CADUS prompt written notice of any claim or allegation received by it that the use of CADUS Technology constitutes an infringement of a Third Party patent or patents. OSI shall have the primary right to control the defense of any such claim against OSI with counsel of its own choosing. CADUS agrees to cooperate with OSI, at OSI's expense, in any reasonable manner deemed by OSI to be necessary in defending such action. Notwithstanding the foregoing, CADUS shall, in its own discretion and at its own cost, be entitled to participate through counsel of its own choosing in any such action. 6.3 Patent Enforcement. (a) With respect to any alleged infringement involving a claim(s) of any patents covering CADUS Technology, CADUS shall have the first right, but not the duty, to institute patent infringement actions against third parties. If CADUS does not institute an infringement proceeding against an offending third party, OSI shall have the right, but not the duty, to institute such an action. 7

(b) The costs and expenses of any action instituted pursuant to this Section 6.3 (including fees of attorneys and other professionals) shall be borne by the Party instituting the action, or, if the Parties elect to cooperate in

5.4 No Refunds. None of the fees paid by OSI to CADUS pursuant to Section 5 shall be refundable for any reason whatsoever. 6. PATENTS 6.1 No Obligation to Prosecute or Maintain Patents. CADUS shall not have any obligation to prosecute or maintain CADUS Patents. Notwithstanding the foregoing, CADUS shall not abandon any of the United States patent applications constituting CADUS Patents set forth on Exhibit B until such time as (i) the corresponding foreign patent application has been published or (ii) CADUS has taken the appropriate steps with the United States Patent and Trademark Office to dedicate such patent application to the public. 6.2 Infringement. OSI shall give CADUS prompt written notice of any claim or allegation received by it that the use of CADUS Technology constitutes an infringement of a Third Party patent or patents. OSI shall have the primary right to control the defense of any such claim against OSI with counsel of its own choosing. CADUS agrees to cooperate with OSI, at OSI's expense, in any reasonable manner deemed by OSI to be necessary in defending such action. Notwithstanding the foregoing, CADUS shall, in its own discretion and at its own cost, be entitled to participate through counsel of its own choosing in any such action. 6.3 Patent Enforcement. (a) With respect to any alleged infringement involving a claim(s) of any patents covering CADUS Technology, CADUS shall have the first right, but not the duty, to institute patent infringement actions against third parties. If CADUS does not institute an infringement proceeding against an offending third party, OSI shall have the right, but not the duty, to institute such an action. 7

(b) The costs and expenses of any action instituted pursuant to this Section 6.3 (including fees of attorneys and other professionals) shall be borne by the Party instituting the action, or, if the Parties elect to cooperate in instituting and maintaining such action, such costs and expenses shall be borne by the Parties in such proportions as they may agree in writing. Each Party shall execute all necessary and proper documents and take such actions as shall be appropriate to allow the other Party to institute and prosecute such infringement actions (if such other Party has the right to institute and prosecute such infringement actions pursuant to this Section 6.3). Any award paid by Third Parties as a result of such an infringement action (whether by way of settlement or otherwise) shall be paid to the Party who instituted and maintained such action, or, if both Parties instituted and maintained such action, such award shall be allocated among the Parties in proportion to their respective contributions to the costs and expenses incurred in such action, or as they may have otherwise agreed. Notwithstanding the above, CADUS shall receive 25% of any such award by way of settlement or otherwise after deducting legal and other reasonable expenses. 7. TERM AND TERMINATION 7.1 Term. This Agreement shall become effective as of the Effective Date and shall remain in full force and effect until terminated as provided in this Section 7. 7.2 Termination by OSI. OSI may terminate this Agreement at any time by giving CADUS thirty (30) days prior written notice of termination. 7.3 Termination for Breach. Failure by either Party to comply with any of the obligations contained in this Agreement shall entitle the other Party to give to the defaulting Party notice specifying the nature of the default and requiring it to cure such default. If such default is not cured within 30 days after the receipt of such notice, the notifying Party shall be 8

entitled, without prejudice to any of its other rights conferred on it by this Agreement, in addition to any other

(b) The costs and expenses of any action instituted pursuant to this Section 6.3 (including fees of attorneys and other professionals) shall be borne by the Party instituting the action, or, if the Parties elect to cooperate in instituting and maintaining such action, such costs and expenses shall be borne by the Parties in such proportions as they may agree in writing. Each Party shall execute all necessary and proper documents and take such actions as shall be appropriate to allow the other Party to institute and prosecute such infringement actions (if such other Party has the right to institute and prosecute such infringement actions pursuant to this Section 6.3). Any award paid by Third Parties as a result of such an infringement action (whether by way of settlement or otherwise) shall be paid to the Party who instituted and maintained such action, or, if both Parties instituted and maintained such action, such award shall be allocated among the Parties in proportion to their respective contributions to the costs and expenses incurred in such action, or as they may have otherwise agreed. Notwithstanding the above, CADUS shall receive 25% of any such award by way of settlement or otherwise after deducting legal and other reasonable expenses. 7. TERM AND TERMINATION 7.1 Term. This Agreement shall become effective as of the Effective Date and shall remain in full force and effect until terminated as provided in this Section 7. 7.2 Termination by OSI. OSI may terminate this Agreement at any time by giving CADUS thirty (30) days prior written notice of termination. 7.3 Termination for Breach. Failure by either Party to comply with any of the obligations contained in this Agreement shall entitle the other Party to give to the defaulting Party notice specifying the nature of the default and requiring it to cure such default. If such default is not cured within 30 days after the receipt of such notice, the notifying Party shall be 8

entitled, without prejudice to any of its other rights conferred on it by this Agreement, in addition to any other remedies available to it by law or in equity, to terminate this Agreement by giving written notice to take effect immediately upon delivery of such notice. The right of either Party to terminate this Agreement shall not be affected in any way by its waiver or failure to take action with respect to any previous default. 7.4 Termination for Bankruptcy. CADUS may terminate this Agreement if, at any time, OSI shall file in any court or agency pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of OSI or of its assets, or if OSI proposes a written agreement of composition or extension of its debts, or if OSI shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after the filing thereof, or if OSI shall propose or be a party to any dissolution or liquidation, or if OSI shall make an assignment for the benefit of creditors. 7.5 No Termination in Event of CADUS Bankruptcy. CADUS and OSI acknowledge that this Agreement and the license granted herein comes within Section 365(n) of Title 11, United States Code (the "Bankruptcy Code"). CADUS acknowledges that if CADUS, as a debtor in possession, or a trustee in bankruptcy in a case under the Bankruptcy Code, rejects the Purchase Agreement or this Agreement, OSI may elect to retain its rights under this Agreement as provided in Section 365(n) of the Bankruptcy Code. Upon written request of OSI to CADUS or the bankruptcy trustee, CADUS shall not interfere with the rights of OSI as provided in this Agreement. 9

7.6 Survival of Certain Provisions. The following provisions of this Agreement will survive the termination of this Agreement: Sections 2.1, 3.5, 4.2, 4.3, 4.4, 8, 9, 10 and 11. 8. DISPUTE RESOLUTION

entitled, without prejudice to any of its other rights conferred on it by this Agreement, in addition to any other remedies available to it by law or in equity, to terminate this Agreement by giving written notice to take effect immediately upon delivery of such notice. The right of either Party to terminate this Agreement shall not be affected in any way by its waiver or failure to take action with respect to any previous default. 7.4 Termination for Bankruptcy. CADUS may terminate this Agreement if, at any time, OSI shall file in any court or agency pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of OSI or of its assets, or if OSI proposes a written agreement of composition or extension of its debts, or if OSI shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after the filing thereof, or if OSI shall propose or be a party to any dissolution or liquidation, or if OSI shall make an assignment for the benefit of creditors. 7.5 No Termination in Event of CADUS Bankruptcy. CADUS and OSI acknowledge that this Agreement and the license granted herein comes within Section 365(n) of Title 11, United States Code (the "Bankruptcy Code"). CADUS acknowledges that if CADUS, as a debtor in possession, or a trustee in bankruptcy in a case under the Bankruptcy Code, rejects the Purchase Agreement or this Agreement, OSI may elect to retain its rights under this Agreement as provided in Section 365(n) of the Bankruptcy Code. Upon written request of OSI to CADUS or the bankruptcy trustee, CADUS shall not interfere with the rights of OSI as provided in this Agreement. 9

7.6 Survival of Certain Provisions. The following provisions of this Agreement will survive the termination of this Agreement: Sections 2.1, 3.5, 4.2, 4.3, 4.4, 8, 9, 10 and 11. 8. DISPUTE RESOLUTION 8.1 Dispute Resolution. If one of the Parties hereto declares that a dispute between the Parties has arisen related to this Agreement, such dispute shall, in the first instance, be the subject of good faith negotiations between the Parties to resolve such dispute. Should the negotiations not lead to a settlement of the dispute within thirty (30) days of the date of the meeting, the Parties shall refer the dispute to a mutually acceptable mediation service to resolve the dispute. The mediation shall be attended by individuals from within each Party who have decisionmaking authority with respect to the matter in question. If the mediation does not lead to a settlement of the dispute within thirty (30) days of the date of the meeting, then the Parties shall submit the issue to arbitration before a panel of arbitrators under the commercial rules of the American Arbitration Association. Unless the Parties otherwise agree, the arbitration will be held in New York, New York. The panel of arbitrators shall consist of three parties: one selected by each Party, as well as a disinterested third party that the two arbitrators shall name. The third arbitrator shall be a person who has had experience in the business of biotechnology licensing. If a qualified person in this field cannot be found and agreed upon, the two arbitrators shall use their own discretion and select a third arbitrator with qualifications as they deem appropriate. The three arbitrators shall be given full power to hear and finally determine and dispose of all disputes between the parties that may arise from or that are related to this Agreement. The arbitrator will make their ruling in writing no later than thirty (30) days after the hearing. The decision of two of the three arbitrators will be binding 10

on the Parties. No Party has a right to appeal the ruling, to any court or otherwise. Judgment upon the decision rendered may be entered in any court having jurisdiction or application may be made to such court of a judicial acceptance of the award and an order of enforcement, as the case may be. Each Party shall pay its own attorney's fees. All fees and expenses payable with respect to the mediation and arbitration proceedings shall be shared by both Parties during the course of the mediation and arbitration proceedings, but, in the case of arbitration, shall be reimbursed in favor of the prevailing Party after the arbitration ruling is rendered. Notwithstanding this Section 8.1, CADUS shall have the right to seek injunctive relief pursuant to Section 11.12 hereof.

7.6 Survival of Certain Provisions. The following provisions of this Agreement will survive the termination of this Agreement: Sections 2.1, 3.5, 4.2, 4.3, 4.4, 8, 9, 10 and 11. 8. DISPUTE RESOLUTION 8.1 Dispute Resolution. If one of the Parties hereto declares that a dispute between the Parties has arisen related to this Agreement, such dispute shall, in the first instance, be the subject of good faith negotiations between the Parties to resolve such dispute. Should the negotiations not lead to a settlement of the dispute within thirty (30) days of the date of the meeting, the Parties shall refer the dispute to a mutually acceptable mediation service to resolve the dispute. The mediation shall be attended by individuals from within each Party who have decisionmaking authority with respect to the matter in question. If the mediation does not lead to a settlement of the dispute within thirty (30) days of the date of the meeting, then the Parties shall submit the issue to arbitration before a panel of arbitrators under the commercial rules of the American Arbitration Association. Unless the Parties otherwise agree, the arbitration will be held in New York, New York. The panel of arbitrators shall consist of three parties: one selected by each Party, as well as a disinterested third party that the two arbitrators shall name. The third arbitrator shall be a person who has had experience in the business of biotechnology licensing. If a qualified person in this field cannot be found and agreed upon, the two arbitrators shall use their own discretion and select a third arbitrator with qualifications as they deem appropriate. The three arbitrators shall be given full power to hear and finally determine and dispose of all disputes between the parties that may arise from or that are related to this Agreement. The arbitrator will make their ruling in writing no later than thirty (30) days after the hearing. The decision of two of the three arbitrators will be binding 10

on the Parties. No Party has a right to appeal the ruling, to any court or otherwise. Judgment upon the decision rendered may be entered in any court having jurisdiction or application may be made to such court of a judicial acceptance of the award and an order of enforcement, as the case may be. Each Party shall pay its own attorney's fees. All fees and expenses payable with respect to the mediation and arbitration proceedings shall be shared by both Parties during the course of the mediation and arbitration proceedings, but, in the case of arbitration, shall be reimbursed in favor of the prevailing Party after the arbitration ruling is rendered. Notwithstanding this Section 8.1, CADUS shall have the right to seek injunctive relief pursuant to Section 11.12 hereof. 9. INDEMNITY. INSURANCE AND REPRESENTATIONS 9.1 Indemnity. OSI agrees to indemnify, hold harmless and defend CADUS, its directors, officers, employees and agents against any and all claims, suits, losses, damages, costs, fees and expenses, including attorney fees, resulting from or arising out of the exercise of this license, including from OSI's use, storage or disposal of the Covered Material or manufacture, distribution or sale or Product(s), unless such losses, damages, costs, fees and expenses arise from the use of CADUS Technology constituting an infringement of a Third Party patent or patents. CADUS shall not be responsible for the negligence or intentional wrongdoing of OSI. 9.2 Insurance. At the time of its sale of Product(s), OSI shall maintain in force at its sole cost and expense, with reputable insurance companies, general liability insurance and products liability insurance coverage that names CADUS as a beneficiary and protects against liability under Section 9.1 above in such amount as is customary in the 11

industry. CADUS shall have the right to ascertain from time to time that such coverage exists, such right to be exercised in a reasonable manner. 9.3 Warranties and Representations. Nothing in this Agreement shall be deemed to be a representation or warranty by CADUS of the validity of any of the CADUS Patents or the accuracy, safety, efficacy or usefulness for any purpose of any technology licensed hereunder. CADUS shall have no obligation, express or implied, to supervise, monitor, review or otherwise assume responsibility for the production, manufacture, testing, marketing

on the Parties. No Party has a right to appeal the ruling, to any court or otherwise. Judgment upon the decision rendered may be entered in any court having jurisdiction or application may be made to such court of a judicial acceptance of the award and an order of enforcement, as the case may be. Each Party shall pay its own attorney's fees. All fees and expenses payable with respect to the mediation and arbitration proceedings shall be shared by both Parties during the course of the mediation and arbitration proceedings, but, in the case of arbitration, shall be reimbursed in favor of the prevailing Party after the arbitration ruling is rendered. Notwithstanding this Section 8.1, CADUS shall have the right to seek injunctive relief pursuant to Section 11.12 hereof. 9. INDEMNITY. INSURANCE AND REPRESENTATIONS 9.1 Indemnity. OSI agrees to indemnify, hold harmless and defend CADUS, its directors, officers, employees and agents against any and all claims, suits, losses, damages, costs, fees and expenses, including attorney fees, resulting from or arising out of the exercise of this license, including from OSI's use, storage or disposal of the Covered Material or manufacture, distribution or sale or Product(s), unless such losses, damages, costs, fees and expenses arise from the use of CADUS Technology constituting an infringement of a Third Party patent or patents. CADUS shall not be responsible for the negligence or intentional wrongdoing of OSI. 9.2 Insurance. At the time of its sale of Product(s), OSI shall maintain in force at its sole cost and expense, with reputable insurance companies, general liability insurance and products liability insurance coverage that names CADUS as a beneficiary and protects against liability under Section 9.1 above in such amount as is customary in the 11

industry. CADUS shall have the right to ascertain from time to time that such coverage exists, such right to be exercised in a reasonable manner. 9.3 Warranties and Representations. Nothing in this Agreement shall be deemed to be a representation or warranty by CADUS of the validity of any of the CADUS Patents or the accuracy, safety, efficacy or usefulness for any purpose of any technology licensed hereunder. CADUS shall have no obligation, express or implied, to supervise, monitor, review or otherwise assume responsibility for the production, manufacture, testing, marketing or sale of any Product(s), and CADUS shall have no liability whatsoever to OSI or any Third Parties for or on account of any injury, loss or damage, of any kind or nature, sustained by, or any damage assessed or asserted against, or any other liability incurred by or imposed upon OSI, its affiliates or sublicensees, or any other person or entity arising out of or in connection with or resulting from: (i) the production, use or sale of any Product(s); (ii) the use of any CADUS Technology; or (iii) any advertising or other promotional activities with respect to any of the foregoing. 10. CONFIDENTIALITY 10.1 CADUS Technology. All CADUS Technology and Covered Material that is disclosed or provided to OSI shall be maintained by OSI in confidence and shall not be disclosed to any other person, firm or agency, governmental or private, or used for purposes other than those set forth in this Agreement, without the prior written consent of CADUS, except to the extent that such information: (i) is known at the time of its receipt by OSI as documented by written records dated prior to such disclosure; 12

(ii) is in the public domain other than through the fault of OSI; (iii) is subsequently disclosed to OSI by a Third Party who may lawfully do so and who is not under an obligation of confidentiality to CADUS; or (iv) is required to be disclosed in a judicial or administrative proceeding after legal remedies for maintaining the

industry. CADUS shall have the right to ascertain from time to time that such coverage exists, such right to be exercised in a reasonable manner. 9.3 Warranties and Representations. Nothing in this Agreement shall be deemed to be a representation or warranty by CADUS of the validity of any of the CADUS Patents or the accuracy, safety, efficacy or usefulness for any purpose of any technology licensed hereunder. CADUS shall have no obligation, express or implied, to supervise, monitor, review or otherwise assume responsibility for the production, manufacture, testing, marketing or sale of any Product(s), and CADUS shall have no liability whatsoever to OSI or any Third Parties for or on account of any injury, loss or damage, of any kind or nature, sustained by, or any damage assessed or asserted against, or any other liability incurred by or imposed upon OSI, its affiliates or sublicensees, or any other person or entity arising out of or in connection with or resulting from: (i) the production, use or sale of any Product(s); (ii) the use of any CADUS Technology; or (iii) any advertising or other promotional activities with respect to any of the foregoing. 10. CONFIDENTIALITY 10.1 CADUS Technology. All CADUS Technology and Covered Material that is disclosed or provided to OSI shall be maintained by OSI in confidence and shall not be disclosed to any other person, firm or agency, governmental or private, or used for purposes other than those set forth in this Agreement, without the prior written consent of CADUS, except to the extent that such information: (i) is known at the time of its receipt by OSI as documented by written records dated prior to such disclosure; 12

(ii) is in the public domain other than through the fault of OSI; (iii) is subsequently disclosed to OSI by a Third Party who may lawfully do so and who is not under an obligation of confidentiality to CADUS; or (iv) is required to be disclosed in a judicial or administrative proceeding after legal remedies for maintaining the subject matter in confidence have been exhausted. 10.2 Duration of Confidentiality Obligation. OSI's obligations of confidentiality shall continue during the term of this Agreement and for a period of five years thereafter. 11. MISCELLANEOUS 11.1 Relationship of Parties. Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, employer-employee or joint venture relationship between the Parties. No Party shall incur any debts or make any commitments for the other. 11.2 Assignment. Neither Party shall be entitled to assign its rights or transfer its obligations hereunder without the express written consent of the other Party hereto, except that CADUS may assign its rights and transfer its obligations hereunder to a purchaser of CADUS Technology and OSI may assign its rights and transfer its obligations hereunder to any assignee of all or substantially all of its assets. No assignment and transfer shall be valid and effective unless and until the assignee/transferee shall agree in writing to be bound by the provisions of this Agreement. 13

11.3 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 11.4 Notice. Any notice or request required or permitted to be given under or in connection with this Agreement

(ii) is in the public domain other than through the fault of OSI; (iii) is subsequently disclosed to OSI by a Third Party who may lawfully do so and who is not under an obligation of confidentiality to CADUS; or (iv) is required to be disclosed in a judicial or administrative proceeding after legal remedies for maintaining the subject matter in confidence have been exhausted. 10.2 Duration of Confidentiality Obligation. OSI's obligations of confidentiality shall continue during the term of this Agreement and for a period of five years thereafter. 11. MISCELLANEOUS 11.1 Relationship of Parties. Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, employer-employee or joint venture relationship between the Parties. No Party shall incur any debts or make any commitments for the other. 11.2 Assignment. Neither Party shall be entitled to assign its rights or transfer its obligations hereunder without the express written consent of the other Party hereto, except that CADUS may assign its rights and transfer its obligations hereunder to a purchaser of CADUS Technology and OSI may assign its rights and transfer its obligations hereunder to any assignee of all or substantially all of its assets. No assignment and transfer shall be valid and effective unless and until the assignee/transferee shall agree in writing to be bound by the provisions of this Agreement. 13

11.3 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 11.4 Notice. Any notice or request required or permitted to be given under or in connection with this Agreement (other than requests pursuant to Section 4.1 hereof) shall be deemed to have been sufficiently given in writing and personally delivered or sent by registered or certified mail (return receipt requested), facsimile transmission (receipt verified), express courier service (signature required), or telegram, prepaid, to the Party for which such notice is intended, at the address set forth for such Party below: (a) In the case of OSI, to: OSI Pharmaceuticals, Inc. 106 Charles Lindbergh Boulevard Uniondale, New York 11533 Attention: President Facsimile No.: (516) 745-6429 with a copy to: Squadron, Ellenoff, Plesent & Sheinfeld, LLP 551 Fifth Avenue New York, New York 10176 Attention: Joel I. Papernik, Esq. Facsimile No.: (212) 697-6686 (b) In the case of CADUS, to: Cadus Pharmaceutical Corporation 767 Fifth Avenue New York, New York 10153 Attention: President Facsimile No.: (212) 750-5841 14

With a copy to:

11.3 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 11.4 Notice. Any notice or request required or permitted to be given under or in connection with this Agreement (other than requests pursuant to Section 4.1 hereof) shall be deemed to have been sufficiently given in writing and personally delivered or sent by registered or certified mail (return receipt requested), facsimile transmission (receipt verified), express courier service (signature required), or telegram, prepaid, to the Party for which such notice is intended, at the address set forth for such Party below: (a) In the case of OSI, to: OSI Pharmaceuticals, Inc. 106 Charles Lindbergh Boulevard Uniondale, New York 11533 Attention: President Facsimile No.: (516) 745-6429 with a copy to: Squadron, Ellenoff, Plesent & Sheinfeld, LLP 551 Fifth Avenue New York, New York 10176 Attention: Joel I. Papernik, Esq. Facsimile No.: (212) 697-6686 (b) In the case of CADUS, to: Cadus Pharmaceutical Corporation 767 Fifth Avenue New York, New York 10153 Attention: President Facsimile No.: (212) 750-5841 14

With a copy to: Morrison Cohen Singer & Weinstein, LLP 750 Lexington Avenue New York, New York 10022 Attention: Salomon R. Sassoon, Esq. Facsimile No.: (212) 735-8708 or to such other address for such Party as it shall have specified by like notice to the other Party, provided that notices of a change of address shall be effective only upon receipt thereof. If sent by mail, facsimile transmission, express courier service, or telegram, the date of mailing or transmission shall be deemed to be the date on which such notice or request has been given. 11.5 Use of Name. Except as otherwise provided herein, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name or trademark of the other Party for any purpose in connection with the performance of this Agreement. 11.6 Waiver. A waiver by either Party of any of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any subsequent breach hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party. 11.7 Export Control Laws. OSI agrees to abide by all laws and regulations of the United States controlling the export of technical data, computer software, biological materials, laboratory prototypes and other commodities and technology. 15

With a copy to: Morrison Cohen Singer & Weinstein, LLP 750 Lexington Avenue New York, New York 10022 Attention: Salomon R. Sassoon, Esq. Facsimile No.: (212) 735-8708 or to such other address for such Party as it shall have specified by like notice to the other Party, provided that notices of a change of address shall be effective only upon receipt thereof. If sent by mail, facsimile transmission, express courier service, or telegram, the date of mailing or transmission shall be deemed to be the date on which such notice or request has been given. 11.5 Use of Name. Except as otherwise provided herein, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name or trademark of the other Party for any purpose in connection with the performance of this Agreement. 11.6 Waiver. A waiver by either Party of any of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any subsequent breach hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party. 11.7 Export Control Laws. OSI agrees to abide by all laws and regulations of the United States controlling the export of technical data, computer software, biological materials, laboratory prototypes and other commodities and technology. 15

11.8 Severability. When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement, and the Parties shall negotiate in good faith to modify this Agreement to preserve (to the extent possible) their original intent. 11.9 Amendment. No amendment, modification or supplement of any provisions of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 11.10 Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, without regard to its choice of law principles. 11.11 Entire Agreement. This Agreement sets forth the entire agreement and understanding between the Parties as to the subject matter hereof and supercedes any previous agreements and understandings between the Parties with respect to the subject matter hereof including without limitation the Technology License Agreement between the Parties dated as of July 30, 1999. 11.12 Injunctive Relief. OSI acknowledges that, in the event of its breach or threatened breach of any of the provisions of this Agreement, CADUS would sustain great and irreparable injury and damage. Therefore, in addition to any other remedies which CADUS may have under this Agreement or otherwise, CADUS shall be entitled to an injunction issued by any court of competent jurisdiction restraining such breach or threatened breach. This 16

Section 11.12 shall not, however, be construed as a waiver of any of the rights which CADUS may have for damages or otherwise.

11.8 Severability. When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement, and the Parties shall negotiate in good faith to modify this Agreement to preserve (to the extent possible) their original intent. 11.9 Amendment. No amendment, modification or supplement of any provisions of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 11.10 Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, without regard to its choice of law principles. 11.11 Entire Agreement. This Agreement sets forth the entire agreement and understanding between the Parties as to the subject matter hereof and supercedes any previous agreements and understandings between the Parties with respect to the subject matter hereof including without limitation the Technology License Agreement between the Parties dated as of July 30, 1999. 11.12 Injunctive Relief. OSI acknowledges that, in the event of its breach or threatened breach of any of the provisions of this Agreement, CADUS would sustain great and irreparable injury and damage. Therefore, in addition to any other remedies which CADUS may have under this Agreement or otherwise, CADUS shall be entitled to an injunction issued by any court of competent jurisdiction restraining such breach or threatened breach. This 16

Section 11.12 shall not, however, be construed as a waiver of any of the rights which CADUS may have for damages or otherwise. 11.13 Counterparts. This Agreement may be executed simultaneously in any number of counterparts, any one of which need not contain the signature of more than one Party but all such counterparts taken together shall constitute one and the same agreement. 11.14 Descriptive Headings. The descriptive headings of this Agreement are for convenience only and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement. IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed by its duly authorized officer as of the date first above written. CADUS PHARMACEUTICAL CORPORATION
By: /s/ Charles Woler ----------------------------Charles Woler, President

OSI PHARMACEUTICALS, INC.
By: /s/ Colin Goddard ----------------------------Colin Goddard, President and Chief Executive Officer

17

EXHIBIT A

Section 11.12 shall not, however, be construed as a waiver of any of the rights which CADUS may have for damages or otherwise. 11.13 Counterparts. This Agreement may be executed simultaneously in any number of counterparts, any one of which need not contain the signature of more than one Party but all such counterparts taken together shall constitute one and the same agreement. 11.14 Descriptive Headings. The descriptive headings of this Agreement are for convenience only and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement. IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed by its duly authorized officer as of the date first above written. CADUS PHARMACEUTICAL CORPORATION
By: /s/ Charles Woler ----------------------------Charles Woler, President

OSI PHARMACEUTICALS, INC.
By: /s/ Colin Goddard ----------------------------Colin Goddard, President and Chief Executive Officer

17

EXHIBIT A
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------1141 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------1316 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------1455 a FUS1p-HIS3 bar1::hisG far1-1 his3 leu2 ste14::TRP1 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------1892 a FUS1p-HIS3 bar1::hisG his3 leu2 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------4600 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 ste4*2393 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------6259 a FUS1p-HIS3 bar1::hisG far1-1 his3 leu2 lys2 ste14::trp1::LYS2 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------6492 a FUS1p-HIS3 bar1::hisG far1*1442 his3 leu2 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------6550 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 npr2::nFUS1p-CAN1 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------7967 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i3 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------8342 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sE10K his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------8344 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sE10K;D229S his3 leu2

EXHIBIT A
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------1141 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------1316 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------1455 a FUS1p-HIS3 bar1::hisG far1-1 his3 leu2 ste14::TRP1 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------1892 a FUS1p-HIS3 bar1::hisG his3 leu2 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------4600 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 ste4*2393 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------6259 a FUS1p-HIS3 bar1::hisG far1-1 his3 leu2 lys2 ste14::trp1::LYS2 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------6492 a FUS1p-HIS3 bar1::hisG far1*1442 his3 leu2 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------6550 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 npr2::nFUS1p-CAN1 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------7967 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i3 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------8342 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sE10K his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------8344 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sE10K;D229S his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

A-1
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------8350 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sD229S his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------8362 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sE10K his3 leu2 lys2 CP1584 CP1 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------8719 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9034 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@16(S270P) his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9434 @ FUS1p-HIS3 can1 cyh2 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9438 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9571 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9595 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2 his3 lys2 CP1584 CP3 ste14::trp1::LYS2 ste3*1156 tbt1-1 ura3 --------------------------------------------------------------------------------------------------------9603 @ D314) FUS1p-HIS3 L291, can1 far1*1442 gpa1(41)-G@16(S270P, his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------8350 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sD229S his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------8362 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sE10K his3 leu2 lys2 CP1584 CP1 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------8719 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9034 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@16(S270P) his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9434 @ FUS1p-HIS3 can1 cyh2 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9438 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9571 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9595 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2 his3 lys2 CP1584 CP3 ste14::trp1::LYS2 ste3*1156 tbt1-1 ura3 --------------------------------------------------------------------------------------------------------9603 @ D314) FUS1p-HIS3 L291, can1 far1*1442 gpa1(41)-G@16(S270P, his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9664 a FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9791 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

A-2
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------9805 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 CP3390 CP4 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9863 @ FUS1p-HIS3 ade2*3447ade8*3457 can1 far1*1442 gpa1(41)-G@16(S270P) his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9875 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1p-rG@sE10K his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9881 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 CP1947 CP3 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10091 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10097 trp1-289 --------------------------------------------------------------------------------------------------------10098 gal4 --------------------------------------------------------------------------------------------------------10099 ade --------------------------------------------------------------------------------------------------------10100 leu --------------------------------------------------------------------------------------------------------10101 lys ---------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------9805 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 CP3390 CP4 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9863 @ FUS1p-HIS3 ade2*3447ade8*3457 can1 far1*1442 gpa1(41)-G@16(S270P) his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9875 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1p-rG@sE10K his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------9881 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 CP1947 CP3 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10091 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10097 trp1-289 --------------------------------------------------------------------------------------------------------10098 gal4 --------------------------------------------------------------------------------------------------------10099 ade --------------------------------------------------------------------------------------------------------10100 leu --------------------------------------------------------------------------------------------------------10101 lys --------------------------------------------------------------------------------------------------------10103 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 cyh2 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

A-3
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------10106 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1p-rG@sE10K;D229S his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10131 @ FUS1p-HIS3 GPA1-3907 ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10132 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1(41)-G@16(S270P) his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10151 @ FUS1p-HIS3 GPA1p-G@sD229S ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10175 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1p-rG@sD229S his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10199 ura --------------------------------------------------------------------------------------------------------10319 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1(41)-G@i3 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10519 @ FUS1p-HIS3 GPA1p-G@sE10K ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10560 @ FUS1p-HIS3 GPA1-3907 ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 sst2*1056 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------10106 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1p-rG@sE10K;D229S his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10131 @ FUS1p-HIS3 GPA1-3907 ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10132 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1(41)-G@16(S270P) his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10151 @ FUS1p-HIS3 GPA1p-G@sD229S ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10175 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1p-rG@sD229S his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10199 ura --------------------------------------------------------------------------------------------------------10319 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1(41)-G@i3 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10519 @ FUS1p-HIS3 GPA1p-G@sE10K ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10560 @ FUS1p-HIS3 GPA1-3907 ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 sst2*1056 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10562 @ FUS1p-HIS3 S270P can1 far1*1442 gpa1(41)-G@16 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10565 @ FUS1p-HIS3 GPA1p-G@sD229S can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

A-4
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------10652 @ FUS1p-HIS3 GPA1p-ratG@i1 ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10734 a FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste2* ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10771 a ade1 cdc24-1 his2 leu2 trp1 ura3 --------------------------------------------------------------------------------------------------------10772 a ade1 cdc42-1 his2 leu2 trp1 ura3 --------------------------------------------------------------------------------------------------------10942 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste18g601-4060 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10981 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11063 @ FUS1p-HIS3 GPA1p-G@sE10K can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11066 @ FUS1p-HIS3 GPA1p-G@sE10K;D229S ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------10652 @ FUS1p-HIS3 GPA1p-ratG@i1 ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10734 a FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste2* ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10771 a ade1 cdc24-1 his2 leu2 trp1 ura3 --------------------------------------------------------------------------------------------------------10772 a ade1 cdc42-1 his2 leu2 trp1 ura3 --------------------------------------------------------------------------------------------------------10942 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste18g601-4060 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------10981 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11063 @ FUS1p-HIS3 GPA1p-G@sE10K can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11066 @ FUS1p-HIS3 GPA1p-G@sE10K;D229S ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11067 @ FUS1p-HIS3 GPA1p-G@sE10K;D229S can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11366 a FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste2* ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11368 a FUS1p-HIS3 can1 far1*1442 gpa1p-G@sD229S his3 leu2 lys2 ste14::trp1::LYS2 ste2* ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

A-5
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------11647 a FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11714 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sG226A his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11715 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sQ227L his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11777 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 CP1947 CP3 ste14::trp1::LYS2 ste18g601-4060 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11778 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 CP1179 CP1 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11845 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1*1163 his3 leu2 lys2 sst2*1056 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12025 @ FUS1p-HIS3 GPA1p-G@sD229S can1 far1*1442 leu2 lys2 ste14::trp1::LYS2 ste3*1156 stp22::TRP1ste18g6-3841 tbt1-1 trp1his3ade2*3447ade8*3457 ura3 --------------------------------------------------------------------------------------------------------12201 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12220 a FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste2*1154 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12357 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------11647 a FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11714 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sG226A his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11715 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sQ227L his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11777 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 CP1947 CP3 ste14::trp1::LYS2 ste18g601-4060 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11778 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 CP1179 CP1 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------11845 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 far1*1442 gpa1*1163 his3 leu2 lys2 sst2*1056 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12025 @ FUS1p-HIS3 GPA1p-G@sD229S can1 far1*1442 leu2 lys2 ste14::trp1::LYS2 ste3*1156 stp22::TRP1ste18g6-3841 tbt1-1 trp1his3ade2*3447ade8*3457 ura3 --------------------------------------------------------------------------------------------------------12201 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12220 a FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste2*1154 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12357 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12444 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 ste5 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

A-6
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------12660 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i3 his3 leu2 lys2 CP1584 CP5 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12670 @ FUS1p-HIS3 GPA1p-G@sN254D can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12872 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2A235T his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12946 @ FUS1p-HIS3 GPA1G@i2(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12949 @ FUS1p-HIS3 GPA1-G@12(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12950 @ FUS1p-HIS3 GPA1-G@q(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12952 @ FUS1p-HIS3 GPA1-G@s(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12954 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18*2377 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12970 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste20::KanR ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12971 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------12660 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i3 his3 leu2 lys2 CP1584 CP5 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12670 @ FUS1p-HIS3 GPA1p-G@sN254D can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12872 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2A235T his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12946 @ FUS1p-HIS3 GPA1G@i2(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12949 @ FUS1p-HIS3 GPA1-G@12(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12950 @ FUS1p-HIS3 GPA1-G@q(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12952 @ FUS1p-HIS3 GPA1-G@s(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12954 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18*2377 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12970 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste20::KanR ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------12971 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste20::KanR ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13189 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 CP1947 CP3 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

A-7
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------13193 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13385 @ FUS1p-HIS3 GPA1G@i2(5) ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 sst2*1056 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13387 @ FUS1p-HIS3 GPA1G@12(5) ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 sst2*1056 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13389 @ FUS1p-HIS3 GPA1G@q(5) ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 sst2*1056 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13391 @ FUS1p-HIS3 GPA1G@s(5) ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 sst2*1056 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13393 @ FUS1p-HIS3 GPA1G@i2(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13395 @ FUS1p-HIS3 GPA1G@12(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13397 @ FUS1p-HIS3 GPA1G@q(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------13193 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13385 @ FUS1p-HIS3 GPA1G@i2(5) ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 sst2*1056 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13387 @ FUS1p-HIS3 GPA1G@12(5) ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 sst2*1056 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13389 @ FUS1p-HIS3 GPA1G@q(5) ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 sst2*1056 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13391 @ FUS1p-HIS3 GPA1G@s(5) ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 sst2*1056 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13393 @ FUS1p-HIS3 GPA1G@i2(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13395 @ FUS1p-HIS3 GPA1G@12(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13397 @ FUS1p-HIS3 GPA1G@q(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13399 @ FUS1p-HIS3 GPA1G@s(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13771 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@16 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13934 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 CP1947 CP4 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3

A-8
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------13937 @ FUS1p-HIS3 can1 cyh2 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste18g26-5261 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13947 @ FUS1p-HIS3 STE18g26-5363 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------14011 @ FUS1p-HIS3 GPA1p-G@sE10K can1 far1*1442 his3 leu2 lys2 CP1584 CP5 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------14012 @ FUS1p-HIS3 GPA1p-G@sD229S can1 far1*1442 leu2 lys2 CP1947 CP5 ste14::trp1::LYS2 ste3*1156 stp22::TRP1ste18g6-3841 tbt1-1 trp1his3ade2*3447ade8*3457 ura3 --------------------------------------------------------------------------------------------------------14016 @ FUS1p-HIS3 can1 far1*1442 gpa1::klURA3 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------14078 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 cyh2 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 ste5*4276 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------14637 @ E10K FUS1p-HIS3 GPA1p-G@s can1 far1*1442 his3 leu2 lys2 pho3*4602 pho4::KAN ste14::trp1::LYS2 ste3*1156 tbt1-1

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------13937 @ FUS1p-HIS3 can1 cyh2 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste18g26-5261 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------13947 @ FUS1p-HIS3 STE18g26-5363 can1 far1*1442 gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------14011 @ FUS1p-HIS3 GPA1p-G@sE10K can1 far1*1442 his3 leu2 lys2 CP1584 CP5 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------14012 @ FUS1p-HIS3 GPA1p-G@sD229S can1 far1*1442 leu2 lys2 CP1947 CP5 ste14::trp1::LYS2 ste3*1156 stp22::TRP1ste18g6-3841 tbt1-1 trp1his3ade2*3447ade8*3457 ura3 --------------------------------------------------------------------------------------------------------14016 @ FUS1p-HIS3 can1 far1*1442 gpa1::klURA3 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------14078 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 cyh2 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 ste5*4276 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------14637 @ E10K FUS1p-HIS3 GPA1p-G@s can1 far1*1442 his3 leu2 lys2 pho3*4602 pho4::KAN ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------14638 @ E10K;A249T FUS1p-HIS3 GPA1p-G@s can1 cyh2 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------14640 @ FUS1p-HIS3 GPA1p-GPA1-G@z(5) can1 cyh2 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------14706 @ ste18g6-3841 GPA+3907 sst2*2 far1*1442 tbt1-1 fus1-HIS3 can1 ste14::trp1::LYS2 ste3*1156 lys2 ura3 leu2 trp1 his3 --------------------------------------------------------------------------------------------------------15070 @ FUS1p-HIS3 GPA1G@z(5) STE18g6-3841 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

A-9
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------15072 @ FUS1p-HIS3 GPA1G@16(6) STE18g6-3841 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------15074 @ FUS1p-HIS3 GPA1G@13(5) STE18g6-3841 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------15203 a lys9 --------------------------------------------------------------------------------------------------------15204 @ lys9 --------------------------------------------------------------------------------------------------------15347 @ FUS1p-HIS3 GPA1G@z(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------15349 @ FUS1p-HIS3 GPA1G@13(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------15351 @ FUS1p-HIS3 GPA1G@16(6) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------15427 @ E10K FUS1p-HIS3 GPA1p-G@s can1 far1*1442 his3 leu2 lys2 CP1766 C pho3*4602 pho4::KAN ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------15072 @ FUS1p-HIS3 GPA1G@16(6) STE18g6-3841 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------15074 @ FUS1p-HIS3 GPA1G@13(5) STE18g6-3841 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------15203 a lys9 --------------------------------------------------------------------------------------------------------15204 @ lys9 --------------------------------------------------------------------------------------------------------15347 @ FUS1p-HIS3 GPA1G@z(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------15349 @ FUS1p-HIS3 GPA1G@13(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------15351 @ FUS1p-HIS3 GPA1G@16(6) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------15427 @ E10K FUS1p-HIS3 GPA1p-G@s can1 far1*1442 his3 leu2 lys2 CP1766 C pho3*4602 pho4::KAN ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------15659 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------15836 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 CP1930 C sst2*2 ste14::trp1::LYS2 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------16160 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g26-5363 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

A-10
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------16463 @ FUS1p-HIS3 GPA1p-G@sD229S can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g26-5363 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------16637 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1::TRP1::nFUS1p-GFPS65T ura3::URA3::nFUS1p-GFPS65T --------------------------------------------------------------------------------------------------------16961 @ FUS1p-HIS3 GPA1p-G@sD229S STE18g6-3841 ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17002 @ FUS1p-HIS3 G@q(1-11)-GPA1(6-467)-G@q(5) STE18g6-3841 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17004 @ FUS1p-HIS3 STE18g6-3841 can1 far1*1442 his3 leu2 lys2 ratG@sE10K-G@q(6) sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17007 @ FUS1p-HIS3 STE18g6-3841 can1 far1*1442 his3 leu2 lys2 ratG@sD229S-G@q(6) sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17008 @ FUS1p-HIS3 GPA1-G@s(6) STE18g6-3841 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17010 @ FUS1p-HIS3 G@q(1-21)-GPA1(24-467)-G@q(5) STE18g6-3841 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------16463 @ FUS1p-HIS3 GPA1p-G@sD229S can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste18g26-5363 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------16637 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1::TRP1::nFUS1p-GFPS65T ura3::URA3::nFUS1p-GFPS65T --------------------------------------------------------------------------------------------------------16961 @ FUS1p-HIS3 GPA1p-G@sD229S STE18g6-3841 ade2*3447 ade8*3457 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17002 @ FUS1p-HIS3 G@q(1-11)-GPA1(6-467)-G@q(5) STE18g6-3841 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17004 @ FUS1p-HIS3 STE18g6-3841 can1 far1*1442 his3 leu2 lys2 ratG@sE10K-G@q(6) sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17007 @ FUS1p-HIS3 STE18g6-3841 can1 far1*1442 his3 leu2 lys2 ratG@sD229S-G@q(6) sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17008 @ FUS1p-HIS3 GPA1-G@s(6) STE18g6-3841 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17010 @ FUS1p-HIS3 G@q(1-21)-GPA1(24-467)-G@q(5) STE18g6-3841 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17012 @ FUS1p-HIS3 G@q(1-11)-GPA1(6-467)-G@q(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17014 @ FUS1p-HIS3 can1 far1*1442 his3 leu2 lys2 ratG@sE10K-G@q(6) sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17016 @ FUS1p-HIS3 can1 far1*1442 his3 leu2 lys2 ratG@sD229S-G@q(6) sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

A-11
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------17018 @ FUS1p-HIS3 GPA1-G@s(6) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17020 @ FUS1p-HIS3 G@q(1-21)-GPA1(24-467)-G@q(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17062 @ FUS1p-HIS3 GPA1-G@i2(5) can1 far1*1442 his3 leu2 lys2 pho3*4602 pho4::KAN sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17063 @ FUS1p-HIS3 GPA1-G@q(5) can1 far1*1442 his3 leu2 lys2 pho3*4602 pho4::KAN sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17426 @ FUS1p-HIS3 his3 lys2 sst2*2 GPA1G@q(5) can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 STE18g26-5363 --------------------------------------------------------------------------------------------------------17549 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 kre1::HisG leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17551 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 kre1::HisG leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------17018 @ FUS1p-HIS3 GPA1-G@s(6) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17020 @ FUS1p-HIS3 G@q(1-21)-GPA1(24-467)-G@q(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17062 @ FUS1p-HIS3 GPA1-G@i2(5) can1 far1*1442 his3 leu2 lys2 pho3*4602 pho4::KAN sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17063 @ FUS1p-HIS3 GPA1-G@q(5) can1 far1*1442 his3 leu2 lys2 pho3*4602 pho4::KAN sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17426 @ FUS1p-HIS3 his3 lys2 sst2*2 GPA1G@q(5) can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 STE18g26-5363 --------------------------------------------------------------------------------------------------------17549 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 kre1::HisG leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17551 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 kre1::HisG leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17553 @ FUS1p-HIS3 STE18g6-3841 can1 far1*1442 gpa1*1163 his3 kre1::HisG leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17555 @ FUS1p-HIS3 STE18g6-3841 can1 far1*1442 gpa1*1163 his3 kre1::HisG leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17624 a FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17625 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-16 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

A-12
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------17626 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-17 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17627 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-39 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17628 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-43 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17629 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-61 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17630 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-63 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17631 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-64 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17632 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 nap-16 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------17626 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-17 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17627 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-39 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17628 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-43 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17629 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-61 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17630 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-63 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17631 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-64 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17632 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 nap-16 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17633 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 nap-17 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17634 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 nap-39 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17635 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 nap-43 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17636 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 nap-61 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

A-13
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------17637 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 nap-63 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17638 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 nap-64 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17749 @ FUS1p-HIS3 GPA1G@s(5) STE18g6-3841 can1 far1*1442 his3 CP1584 CP1 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17750 @ FUS1p-HIS3 GPA1G@s(5) STE18g6-3841 can1 far1*1442 his3 CP1584 CP1 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17751 @ FUS1p-HIS3 GPA1-G@i2(5) can1 dap2*6253 far1*1442 his3 leu2 lys2 sst2*2 ste13*6077 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17843 a FUS1p-HIS3 bar1::hisG far1*1442 gpa1*1163 his3 leu2 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17879 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------17637 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 nap-63 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17638 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 lys2 nap-64 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17749 @ FUS1p-HIS3 GPA1G@s(5) STE18g6-3841 can1 far1*1442 his3 CP1584 CP1 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17750 @ FUS1p-HIS3 GPA1G@s(5) STE18g6-3841 can1 far1*1442 his3 CP1584 CP1 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17751 @ FUS1p-HIS3 GPA1-G@i2(5) can1 dap2*6253 far1*1442 his3 leu2 lys2 sst2*2 ste13*6077 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17843 a FUS1p-HIS3 bar1::hisG far1*1442 gpa1*1163 his3 leu2 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17879 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2::LEU2::PGKp-A2aR lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------17880 a FUS1p-HIS3 bar1::hisG his3 leu2 sst2*1056 ste2*1154 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------18039 @ FUS1p-HIS3 GPA1p-G@sD229S STE18g6-3841 ade2*3447 CP1584 CP1 ade8*3457 can1 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------18043 @ FUS1p-HIS3 GPA1G@o(5) STE18g6-3841 can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------18045 @ FUS1p-HIS3 GPA1G@o(5) can1 far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 ---------------------------------------------------------------------------------------------------------

A-14
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------18158 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-16 sst2*2 ste14::trp1::LYS2 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------18189 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-16 sst2*2 ste14::trp1::LYS2 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------18190 @ FUS1p-HIS3 GPA1G@z(5) STE18g6-3841 can1 far1*1442 his3 kre1::hisG leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------18222 @ FUS1p-HIS3 GPA1G@z(5) STE18g6-3841 can1 far1*1442 his3 CP1947 CP6 kre1::hisG leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------18774 @ FUS1p-HIS3 lys2 can1 far1*1442 his3 leu2 pho3*4602 pho4::KAN sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 GPA1p-GPA1-G@s(6) --------------------------------------------------------------------------------------------------------19029 @ FUS1p-HIS3 G@q(1-21)-GPA1(24-467)-G@q(5) STE18g6-3841 can1 far1*1442 his3 kre1::HisG leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------19039 @ FUS1p-HIS3 GPA1p-GPA1-G@s(6) can1 far1*1442 his3 leu2 CP5226 CP6 lys2 pho3*4602 pho4::KAN sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------18158 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-16 sst2*2 ste14::trp1::LYS2 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------18189 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3 leu2 lys2 nap-16 sst2*2 ste14::trp1::LYS2 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------18190 @ FUS1p-HIS3 GPA1G@z(5) STE18g6-3841 can1 far1*1442 his3 kre1::hisG leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------18222 @ FUS1p-HIS3 GPA1G@z(5) STE18g6-3841 can1 far1*1442 his3 CP1947 CP6 kre1::hisG leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------18774 @ FUS1p-HIS3 lys2 can1 far1*1442 his3 leu2 pho3*4602 pho4::KAN sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 GPA1p-GPA1-G@s(6) --------------------------------------------------------------------------------------------------------19029 @ FUS1p-HIS3 G@q(1-21)-GPA1(24-467)-G@q(5) STE18g6-3841 can1 far1*1442 his3 kre1::HisG leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------19039 @ FUS1p-HIS3 GPA1p-GPA1-G@s(6) can1 far1*1442 his3 leu2 CP5226 CP6 lys2 pho3*4602 pho4::KAN sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------19055 @ FUS1p-HIS3 GPA1p-GPA1-G@s(6) can1 far1*1442 his3 leu2 CP5226 CP1 lys2 pho3*4602 pho4::KAN sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------19063 @ FUS1p-HIS3 GPA1-G@q(5) GPA1G@q(5) can1 far1*1442 his3 CP6513 CP1 leu2 lys2 pho3*4602 pho4::KAN sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------19493 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 GPA1p-G@11(1-11)-GPA1(6-467)-G@q(355-359)-GPA1t --------------------------------------------------------------------------------------------------------19496 @ FUS1p-HIS3 his3 lys2 GPA1G@q(5) can1 cyh2 far1*1442 leu2 pho3*4602 pho4::KANMX2 sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 ura3 trp1::TRP1::STE12p-SV40NLS(MGAPPKKKRKVA)-PHO4(228-312)STE12(1-587,EAS,670-688)-ADH1t ---------------------------------------------------------------------------------------------------------

A-15
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------19507 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 GPA1p-G@q(1-24)-GPA1(27-467)-G@q(355-359)-GPA1t --------------------------------------------------------------------------------------------------------19509 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 GPA1p-G@q(1-32)-GPA1(35-467)-G@q(355-359)-GPA1t --------------------------------------------------------------------------------------------------------19511 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 STE18g6-3841 GPA1p-G@11(1-11)-GPA1(6-467)-G@q(355-359)-GPA1t --------------------------------------------------------------------------------------------------------19512 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 STE18g6-3841 GPA1p-G@11(1-11)-GPA1(6-467)-G@q(355-359)-GPA1t --------------------------------------------------------------------------------------------------------19513 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 STE18g6-3841 ---------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------19507 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 GPA1p-G@q(1-24)-GPA1(27-467)-G@q(355-359)-GPA1t --------------------------------------------------------------------------------------------------------19509 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 GPA1p-G@q(1-32)-GPA1(35-467)-G@q(355-359)-GPA1t --------------------------------------------------------------------------------------------------------19511 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 STE18g6-3841 GPA1p-G@11(1-11)-GPA1(6-467)-G@q(355-359)-GPA1t --------------------------------------------------------------------------------------------------------19512 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 STE18g6-3841 GPA1p-G@11(1-11)-GPA1(6-467)-G@q(355-359)-GPA1t --------------------------------------------------------------------------------------------------------19513 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 STE18g6-3841 --------------------------------------------------------------------------------------------------------19514 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 STE18g6-3841 --------------------------------------------------------------------------------------------------------19515 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 STE18g6-3841 GPA1p-G@q(1-32)-GPA1(35-467)-G@q(355-359)-GPA1t --------------------------------------------------------------------------------------------------------19598 @ FUS1p-HIS3 GPA1-G@i2(5) his3 lys2 can1 far1*1442 leu2 CP6555 CP5 pho3*4602 pho4::KAN sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 --------------------------------------------------------------------------------------------------------19608 @ FUS1p-HIS3 lys2 can1 far1*1442 gpa1*1163 his3 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 STE18g26-5363 GPA1-G@s(5)-5102 --------------------------------------------------------------------------------------------------------19608 @ FUS1p-HIS3 lys2 can1 far1*1442 gpa1*1163 his3 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 STE18g26-5363 GPA1-G@s(5)-5102 --------------------------------------------------------------------------------------------------------19625 @ FUS1p-HIS3 his3 lys2 GPA1G@q(5) can1 cyh2 far1*1442 leu2 CP1930 pho3*4602 pho4::KANMX2 sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 ura3 trp1::TRP1::STE12p-SV40NLS(MGAPPKKKRKVA)-PHO4 (228-312)-STE12(1-587,EAS,670-688)-ADH1t ---------------------------------------------------------------------------------------------------------

A-16
--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------19888 @ FUS1p-HIS3 GPA1p-G@sD229S his3 lys2 ade2*3447 ade8*3457 can1 far1*1442 leu2 ste14::trp1::LYS2 ste18*2377 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 ste18g26-5363 --------------------------------------------------------------------------------------------------------19888 @ FUS1p-HIS3 GPA1p-G@sD229S his3 lys2 ade2*3447 ade8*3457 can1 far1*1442 leu2 ste14::trp1::LYS2 ste18*2377 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 ste18g26-5363 --------------------------------------------------------------------------------------------------------19889 @ FUS1p-HIS3 GPA1p-G@sD229S his3 lys2 ade2*3447 ade8*3457 CP6280 CP5 can1 far1*1442 leu2 ste14::trp1::LYS2 ste18*2377 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 ste18g26-5363 --------------------------------------------------------------------------------------------------------19910 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 GPA1G@z(5) STE18g6-3841 --------------------------------------------------------------------------------------------------------19928 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 CP6490 CP1 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 GPA1G@16(6) ---------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2 --------------------------------------------------------------------------------------------------------19888 @ FUS1p-HIS3 GPA1p-G@sD229S his3 lys2 ade2*3447 ade8*3457 can1 far1*1442 leu2 ste14::trp1::LYS2 ste18*2377 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 ste18g26-5363 --------------------------------------------------------------------------------------------------------19888 @ FUS1p-HIS3 GPA1p-G@sD229S his3 lys2 ade2*3447 ade8*3457 can1 far1*1442 leu2 ste14::trp1::LYS2 ste18*2377 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 ste18g26-5363 --------------------------------------------------------------------------------------------------------19889 @ FUS1p-HIS3 GPA1p-G@sD229S his3 lys2 ade2*3447 ade8*3457 CP6280 CP5 can1 far1*1442 leu2 ste14::trp1::LYS2 ste18*2377 ste3*1156 stp22::hisG tbt1-1 trp1 ura3 ste18g26-5363 --------------------------------------------------------------------------------------------------------19910 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 GPA1G@z(5) STE18g6-3841 --------------------------------------------------------------------------------------------------------19928 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 CP6490 CP1 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3 GPA1G@16(6) ---------------------------------------------------------------------------------------------------------

All Mammalian Cell Lines A-17

EXHIBIT B NOTE: US PROVISIONAL APPLICATIONS HAVE SERIAL NUMBERS STARTING WITH "60" AND DOCKET NUMBER ENDING IN "-1" NOTE: FOREIGN APPLICATIONS ARE SHOWN IN BOLD W/SHADING
Docket No. CPI-012CP9 Serial No. 09/201,396 Title Methods and Compositions for Identifying Receptor Effectors Methods and Compositions for Identifying Receptor Effectors Cells Having Amplified Signal Transduction Pathway Responses and Uses Therefor Yeast Cells Having Mutations in STP22 and Uses Therefor Yeast Cells Having Mutations in CAV1 and Uses Therefor Expression of G Protein Coupled Receptors with Altered Ligand Binding and/or Coupling Properties Cell Based Signal Generation Yeast Alpha Agglutinins and Use Thereof as Indicators of Activation of the Yeast Pheromone Response Pathway Filing Date 11/30/98

CPI-12CP9PC

PCT/US99/27909

11/24/99

CPI-088

09/378,046

8/30/99

CPI-091

09/305,923

5/5/99

CPI-096

09/426,332

10/25/99

CPI-099

09/362,286

7/27/99

CPI-102 CPI-122-l

09/241,888 60/153,300

2/1/99 9/10/99

CPI-123-l

60/139,021

Mating Factor Alpha System for Detection of a Functional Interaction Between A Compound and a Cellular Receptor

6/14/99

B-1

EXHIBIT B NOTE: US PROVISIONAL APPLICATIONS HAVE SERIAL NUMBERS STARTING WITH "60" AND DOCKET NUMBER ENDING IN "-1" NOTE: FOREIGN APPLICATIONS ARE SHOWN IN BOLD W/SHADING
Docket No. CPI-012CP9 Serial No. 09/201,396 Title Methods and Compositions for Identifying Receptor Effectors Methods and Compositions for Identifying Receptor Effectors Cells Having Amplified Signal Transduction Pathway Responses and Uses Therefor Yeast Cells Having Mutations in STP22 and Uses Therefor Yeast Cells Having Mutations in CAV1 and Uses Therefor Expression of G Protein Coupled Receptors with Altered Ligand Binding and/or Coupling Properties Cell Based Signal Generation Yeast Alpha Agglutinins and Use Thereof as Indicators of Activation of the Yeast Pheromone Response Pathway Filing Date 11/30/98

CPI-12CP9PC

PCT/US99/27909

11/24/99

CPI-088

09/378,046

8/30/99

CPI-091

09/305,923

5/5/99

CPI-096

09/426,332

10/25/99

CPI-099

09/362,286

7/27/99

CPI-102 CPI-122-l

09/241,888 60/153,300

2/1/99 9/10/99

CPI-123-l

60/139,021

Mating Factor Alpha System for Detection of a Functional Interaction Between A Compound and a Cellular Receptor

6/14/99

B-1
ARTICLE 5

PERIOD TYPE FISCAL YEAR END PERIOD START PERIOD END CASH SECURITIES RECEIVABLES ALLOWANCES INVENTORY CURRENT ASSETS PP&E DEPRECIATION TOTAL ASSETS CURRENT LIABILITIES BONDS PREFERRED MANDATORY PREFERRED COMMON OTHER SE TOTAL LIABILITY AND EQUITY SALES TOTAL REVENUES CGS

6 MOS SEP 30 2000 OCT 1 1999 MAR 31 2000 76,295,360 10,249,963 871,768 27,289 0 89,176,623 26,447,036 17,310,908 102,827,507 6,969,096 0 0 0 273,493 93,066,006 102,827,507 309,760 15,964,438 471,419

ARTICLE 5

PERIOD TYPE FISCAL YEAR END PERIOD START PERIOD END CASH SECURITIES RECEIVABLES ALLOWANCES INVENTORY CURRENT ASSETS PP&E DEPRECIATION TOTAL ASSETS CURRENT LIABILITIES BONDS PREFERRED MANDATORY PREFERRED COMMON OTHER SE TOTAL LIABILITY AND EQUITY SALES TOTAL REVENUES CGS TOTAL COSTS OTHER EXPENSES LOSS PROVISION INTEREST EXPENSE INCOME PRETAX INCOME TAX INCOME CONTINUING DISCONTINUED EXTRAORDINARY CHANGES NET INCOME EPS BASIC EPS DILUTED

6 MOS SEP 30 2000 OCT 1 1999 MAR 31 2000 76,295,360 10,249,963 871,768 27,289 0 89,176,623 26,447,036 17,310,908 102,827,507 6,969,096 0 0 0 273,493 93,066,006 102,827,507 309,760 15,964,438 471,419 22,158,681 54,569 0 19,885 (1,301,108) 0 0 0 0 0 (1,301,108) (0.06) (0.06)


								
To top